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Abstract 
Clinically relevant chronic itch conditions commonly result from kidney failure, 
cholestasis, and skin disorders like allergic contact dermatitis (ACD). Recently, 
numerous members of the Mas-related G-protein coupled receptor (Mrgpr) family of 
GPCRs have been identified as receptors for non-histaminergic pruritogens. In this thesis, 
I utilized Ca2+ imaging, mouse genetics, and mouse models of disease to determine the 
role of Mrgprs in two non-histaminergic pruritus conditions: cholestasis and ACD. In 
chapter one, I demonstrate that pathophysiologic levels of bilirubin observed in 
cholestasis, bound two Mrgprs, mouse MRGPRA1 and human MRGPRX4, activated 
sensory neurons via Mrgprs, and elicited Mrgpr-dependent pruritus. Genetic deletion of  
either Mrgpra1 or Bvlra, the bilirubin-producing enzyme, attenuated mouse models of 
cholestatic itch. In chapter two, I present evidence that human MRGPRX4 is a bile acid 
receptor. To assess the in vivo relevance of bile acid activation of MRGPRX4, I 
generated a humanized mouse with targeted expression of MRGPRX4 to itch-encoding 
sensory neurons. Bile acids activated MRGPRX4-positive sensory neurons at higher 
levels compared to wild-type (WT) neurons. Compared to WT animals, MRGPRX4-mice 
scratched more upon acute injection of bile acids and in a model of cholestatic itch. In the 
final chapter, I examine the role of recently identified mast-cell expressed Mrgprs, 
murine Mrgprb2 and human MRGPRX2, in pruritus. Here I report that, in contrast to the 
IgE /FcεRI- histamine axis, Mrgprb2 activation of murine mast cells resulted in 
differential release of pruritogenic mediators, excited different subsets of itch-sensory 
neurons, and evoked non-histaminergic itch. In preclinical models of ACD, an 
inflammatory skin disorder, the Mrgprb2-mast cell axis critically regulated itch, and both 
mast cells and Mrgpr agonists were upregulated in human ACD skin. Overall, data from 
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this thesis suggests that targeting MRGPRs (MRGPRX4 for cholestatic itch and 
MRGPRX2 for ACD itch) is a promising strategy for alleviating non-histaminergic itch 
conditions.   
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1. Introduction  
1.1 An introduction to itch  
Itch sensation is transmitted by small-diameter, unmyelinated C-fibers of the 
dorsal root ganglia (DRG) and trigeminal ganglia (TG). Itch fibers exclusively innervate 
skin and terminate in the dorsal horn of the spinal cord where they synapse with 
secondary neurons that transmit signal to brain. Anatomically, itch-sensing neurons are 
indistinguishable from pain-sensing neurons. As such, itch neurons were originally 
hypothesized to be a subpopulation of nociceptive, pain-sensing neurons. However, in 
recent years, this model has been upturned, and itch neurons are now recognized as being 
both molecularly and functionally distinct from pain-sensing counterparts. 
1.1.1 Channels and receptors involved in itch sensation  
A large variety of environmental stimuli ranging from single molecule chemicals 
to physical properties like temperature and force can elicit pain and itch. To detect this 
wide range of nociceptive inputs, sensory neurons utilize a host of channels and receptors. 
For example, many small-diameter pain- and itch-sensing neurons express transient 
receptor potential channel (TRP) V1 and/or TRPA1(Caterina et al., 2000; Caterina et al., 
1999). At 42C, the threshold for noxious heat, TRPV1 fluxes cations and depolarizes 
neurons (Caterina et al., 1999). Similarly, numerous pain-producing chemicals, such as 
cinnamaldehyde and mustard oil, activate sensory neurons via TRPA1(Jordt et al., 2004; 
Macpherson et al., 2007).  
Both TRPV1 and TRPA1 are critical for itch transmission. Pruritogen-responsive 
dorsal horn neurons in mouse, rat, and monkey, are also activated by TRP agonists like 
capsaicin and mustard oil as assessed by in vivo electrophysiological recording (Davidson 
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et al., 2012; Klein et al., 2011; Simone et al., 2004). TRPV1 knockout (-/-) mice, animals 
with well-characterized deficits in pain sensation, have drastically decreased 
histaminergic itch, and TRPA1-/- mice scratch less when injected with chloroquine, a 
non-histaminergic pruritogen (Imamachi et al., 2009; Wilson et al., 2011).  
In addition to channels, itch neurons express receptors capable of detecting 
noxious substances. G-protein coupled receptors (GPCRs) are one major class of itch-
associated receptors. GPCRs are a superfamily of proteins expressed in almost every cell 
in the body that detect stimuli as varied as lipids, ions, and proteins (Fredriksson et al., 
2003; Kroeze et al., 2003; Lagerstrom and Schioth, 2008). GPCRs, 5-hydroxytryptamine 
(serotonin) receptor 1F (Htr1f), mas-related G-protein coupled receptor (Mrgpr) a3, and 
Mrgprd, have been identified by single cell transcriptomics as prominent markers for 
three distinct classes of itch-sensitive afferent neurons (Usoskin et al., 2015). 
Importantly, receptor expression is not completely specific to each class. For example, 
there is some Htr1f expression (9%) detected in the Mrgpra3+ class and vice versa (8%) 
(Usoskin et al., 2015). Htr1f is also expressed in additional classes of sensory neurons 
involved in pain (Ernberg et al., 2000; Sommer, 2004). In contrast, Mrgpra3 and Mrgprd 
are specific to itch neurons, with undetectable expression in non-itch sensory neuron 
classes. 
1.1.2 Itch circuits and itch specificity in spinal cord 
In 2001, the first itch-sensing neurons were identified in the cat spinothalamic 
tract (STT). As determined by electrophysiology, these neurons were histamine-sensitive, 
mechano-insensitive, and thermo-insensitive (Andrew and Craig, 2001). Since this initial 
identification, populations of STT neurons sensitive to cowhage, a non-histaminergic 
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pruritogen, were also identified (Davidson et al., 2007). Itch-sensing STT neurons were 
activated by pain-associated stimuli such as capsaicin and noxious heat. At the time, 
these results were viewed as evidence for itch and pain sensation being transmitted by the 
same neurons and as evidence against the existence of itch-specific neurons (Davidson et 
al., 2007; Schmelz et al., 2003). 
With the advent of mouse genetics, spinal sensory circuits became susceptible to 
more detailed investigation. Since then, genetic analyses have overturned old paradigms 
by providing evidence for two populations of itch-specific neurons in spinal cord, 
Gastrin-related peptide receptor+ (GRPR+) neurons and Natriuretic peptide receptor A+ 
(NPRA+) (Mishra and Hoon, 2013; Sun et al., 2009). Ablation of either GRPR+ or 
NPRA+ neurons in lamina I decreased peripheral itch without alterations in pain behavior 
(Sun et al., 2009). Concordantly, activation of both GRPR with GRP homologs bombesin 
and neuromedin B and NPRA with natriuretic polypeptide elicited pruritus and not pain, 
suggesting labeled-line specificity (Gmerek and Cowan, 1983). Intriguingly, both the 
receptors themselves, GRPR and NPRA, and their respective ligands, GRP and 
natriuretic polypeptide B (NPPB), are believed to be critical for itch signaling. Both 
receptor knockout mice, GRPR-/-, and ligand knockout mice, GRP-/- and NPPB-/-, have 
deficits in acute itch with intact thermal and mechanical pain response (Sun et al., 2009). 
GRP and NPPB have been detected in primary sensory neurons of the DRG (Barry et al., 
2016; Liu et al., 2014; Zhao et al., 2013). However, GRP expression in DRG is 
controversial as numerous groups have been unable to detect GRP transcript and protein 
in DRG. Instead, these labs report GRP expression in spinal cord (Fleming et al., 2012; 
Mishra and Hoon, 2013; Solorzano et al., 2015).  
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In the spinal cord, itch neurons are regulated by interneurons engaged in various 
circuits. One prominent example is a circuit whereby scratch, a painful stimulus, inhibits 
itch sensation. Similar to the circuit model of Gate Control Theory where touch afferents 
activate interneurons that inhibit secondary pain neurons (Melzack and Wall, 1965), pain 
afferents activate basic helix-loop-helix b5 (Bhlhb5)-dependent interneurons which 
inhibit secondary itch neurons (Ross et al., 2010). In mice, silencing TRPV1+ primary 
pain-sensing neurons decreases pain afferent signaling and results in chronic, pathologic 
itch (Lagerstrom et al., 2010). Concordantly, loss of Bhlhb5-dependent interneurons 
results in severe chronic itch and heightened acute itch behavior (Ross et al., 2010).  
Bhlhb5-dependent interneurons gate chemical itch. A different class of 
interneurons, neuropeptide Y (NPY)+ neurons, regulates mechanical itch associated with 
stimulation of hairy skin. Ablation of NPY+ neurons in mice results in pathologic chronic 
itch. In NPY+ neuron-ablated animals, low-threshold (0.02g - 0.4g) mechanical itch is 
upregulated while high-threshold mechanical itch and chemical itch are not (Bourane et 
al., 2015). BhlhB5-/- mice have normal NPY expression (Ross et al., 2010). Similarly, 
NPY+ interneuron ablation spares Bhlhb5-dependent interneurons (Bourane et al., 2015). 
Based on this and corroboratory behavior, NPY+ and BhlhB5-dependent neurons are 
hypothesized to be non-overlapping populations with unique functions of gating 
mechanical and chemical itch respectively. 
1.2 Mas-related G-Protein Coupled Receptors (Mrgprs) in itch biology 
1.2.1 As markers of peripheral itch neurons 
In 2013, itch-specific peripheral neurons were first identified. These neurons 
express Mrgpra3, exclusively innervate epidermis, and are responsive to mechanical 
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stimuli, heat, and numerous pruritogens (Han et al., 2013). Ablation of Mrgpra3+ neurons 
decreases acute pruritus associated with chloroquine, SLIGRL, BAM8-22, histamine, 
endothelin-1, -Me-HT, and two models of chronic itch: allergic and dry skin. 
Importantly, ablation of Mrgpra3+ neurons does not affect pain, and activation of these 
neurons results in exclusive itch. Based on these data, Mrgpra3+ neurons, despite 
expression of pain-associated channels, are hypothesized to be itch specific neurons in 
the peripheral nervous system.  
While Mrgpra3+ neurons are itch-specific, not all Mrgpr-expressing neurons are 
exclusively involved in itch. For example, Mrgprd+ neurons are believed to be a 
population of non-peptidergic mechanical pain-sensing afferents. Genetic ablation of 
Mrgprd+ neurons reduces sensitivity to noxious mechanical injury and not heat or cold 
(Cavanaugh et al., 2009; Rau et al., 2009; Wang and Zylka, 2009). In vivo calcium 
imaging of Mrgprd+ neurons reveals that they are activated by painful pinch (Vrontou et 
al., 2013).  
1.2.2 Initial identification of Mrgprs 
Mrgpra3 is a member of the Mrgpr family of GPCRs. This family was first 
identified in a subtractive cDNA screen between WT and neurogenin1 (Ngn1)-/- mice, 
animals lacking TrkA+, small-diameter nociceptive neurons (Dong et al., 2001). This 
screening strategy biased discovery for nociceptor-specific sequences. Indeed, Mrgpra1, 
the first Mrgpr sequence cloned, was found to be enriched in a subset of nociceptors in 
mouse DRG and TG. Using this sequence as a template, a bioinformatic search identified 
over 50 sequence similar Mrgprs in mice (27 with intact open reading frames). In humans, 
eight intact MRGPR open reading frames were cloned (Dong et al., 2001). Of the human 
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genes, four of them, MRGPRX1-X4, appeared to be most similar to the murine MrgA 
subfamily. However, one-to-one homology between mouse and human sequences could 
not be confidently assigned. In contrast, human MRGPRs: D, E, F, and G all had single-
gene mouse orthologs.  
After initial identification of the Mrgpr family, two subsequent studies used 
degenerate-oligonucleotide PCR to clone a sequence-similar receptor, termed sensory-
neuron specific receptor (SNSR) from rat DRG, brain, and spinal cord tissue (Bender et 
al., 2002; Lembo et al., 2002). Due to sequence similarity, the International Union of 
Basic and Clinical Pharmacology (IUPHAR) has since reclassified SNSRs as Mrgprs 
(Bader et al., 2014). Today, IUPHAR recognizes the existence of several Mrgpr 
subfamilies: A, B, C, D, E, F, G, H, and a primate-specific X.  
1.2.3 Expression and genetic expansion in mice 
Mrgprs are expressed in sensory neurons of the DRG and trigeminal ganglia (TG), 
numerous brain regions, the enteric nervous system, and, more recently, in immune cells 
like dendritic and mast cells. Some Mrgprs, such as Mrgpra1 in mice and MRGPRX1 in 
primates, are specifically expressed in sensory neurons of the DRG and TG (Dong et al., 
2001; Lembo et al., 2002). Others, like Mrgpre, Mrgprf, and Mrgprb2, are expressed in 
different regions and cell types. Mrgpre (MRGPRE in humans) is expressed in numerous 
brain regions of the central nervous system and the enteric nervous system (Avula et al., 
2011; Zhang et al., 2005). Mrgprf is also expressed in the enteric nervous system and in 
smooth muscle cells (Avula et al., 2011). Mrgprb2, a murine receptor, and MRGPRX2, a 
human receptor, are expressed in mast cells (Kashem et al., 2011; McNeil et al., 2015; 
Subramanian et al., 2011a; Subramanian et al., 2011b).  
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Study of Mrgpr function has been complicated by a murine-specific expansion of 
the Mrgpr locus which resulted from an L1 retrotransposon insertion and multiple rounds 
of unequal crossover (Dong et al., 2001; Zylka et al., 2003). Mice express dozens of 
sequence-similar Mrgpr coding sequences, making compensation a likely experimental 
hurdle. With this consideration in mind, our lab has employed a cluster deletion strategy 
(Cluster-/-) to study Mrgpr function in mice. Cluster-/- mice are missing 12 intact Mrgpr 
coding regions. These mice are viable and produce healthy progeny. Compared to WT, 
Cluster-/-  animals have similar numbers of nociceptive neurons and no appreciable 
changes in proportions of sensory neuron type, indicating that Mrgpr expression is not 
important for itch neuron survival or targeting of neuronal fibers to skin. In recent years, 
behavioral studies in Cluster-/- animals and cellular ligand-activity assays have identified  
functional, but not sequence-based, pairings between mouse and human receptors. For 
example, Mrgpra3/c11 are considered the mouse orthologs of MRGPRX1 and Mrgprb2 
the ortholog of MRGPRX2, based on shared response to ligands.  
1.2.4 As itch receptors 
As GPCRs, Mrgprs can engage second messenger pathways in order to change 
cellular function. Mrgprs have been demonstrated to be coupled to numerous G-protein 
subunits and thereby capable of affecting intracellular signaling through a variety of 
pathways (Bader et al., 2014; Han et al., 2002; Solinski et al., 2014). For example, in 
sensory neurons, Mrgpra3 signaling is blocked by both gallein, a Gβγ inhibitor, and 
ruthenium red, a nonspecific inhibitor of numerous TRP channels. These data indicate 
that activation of Mrgpra3 signals through both Gβγ and TRP channels in order to excite 
neurons (Liu et al., 2009). In a divergent signaling pathway, Mrgprc11-associated 
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calcium flux is blocked by inhibitors of phospholipase C (PLC) signaling and not by 
gallein.   
In 2009, Mrgpra3/MRGPRX1 were shown to be receptors for chloroquine, an 
antimalarial drug associated with non-histaminergic itch (Liu et al., 2009). Chloroquine 
elicits intense pruritus in mice in an Mrgpra3-dependent manner. Cluster-/- mice (lacking 
Mrgpra3) are protected from chloroquine itch while having intact serotonin itch, mast 
cell-mediated itch, and pain response (Liu et al., 2009).  
 Chloroquine-associated itch was the first linking of Mrgprs as a receptor for a 
non-histaminergic pruritogen. Since that study, several Mrgprs have been identified as 
receptors for additional non-histaminergic pruritogens including bovine adrenal medulla 
peptide 8-22 (BAM8-22) (Mrgprc11), protease-produced peptides like SLIGRL 
(Mrgprc11), and -alanine (Mrgprd) (Liu et al., 2011). BAM8-22, proteases, and -
alanine all elicit itch in humans without wheal and flare, which provides physiological 
evidence of mast cell involvement (Sikand et al., 2011).  
Both BAM8-22, a ligand for Mrgprc11, and chloroquine, an activator of murine 
Mrgpra3, activate human MRGPRX1(Liu et al., 2009). In this case, ligand-receptor pairs 
highlight a possible functional link between mouse Mrgpra3 and Mrgprc11 receptors. 
Alternatively, SLIGRL, another ligand of Mrgprc11, activates both MRGPRX1 and 
MRGPRX2, linking a single murine Mrgpr to two different human MRGPRs. 
1.2.5 As mast cell - expressed receptors 
Murine Mrgprb2 and human MRGPRX2 are two Mrgprs with specific expression 
in non-neuronal cells. Both receptors are exclusively expressed in mast cells, resident 
sentinel cells of skin, lung, and intestine (McNeil et al., 2015; Subramanian et al., 2011a; 
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Tatemoto et al., 2006). Mast cell granules contain a range of bioactive molecules 
including histamine, serotonin, proteases, prostaglandins, and cytokines (Theoharides et 
al., 2012). Classical studies of mast cell activation have focused on antigen binding IgE 
and cross-linking of IgE receptor. However, numerous basic secretagogue peptides 
including various toxins, neuropeptides, and hormones can activate mast cells through 
non-IgE mechanisms (McNeil et al., 2015; Solinski et al., 2014; Subramanian et al., 
2011a; Subramanian et al., 2011b; Tatemoto et al., 2006). Recently, Mrgprb2/X2 have 
been identified as the long sought after basic secretagogue receptors that are activated by 
THIQ motif-containing small molecules and positively charged compounds. 
1.3 Non-histaminergic itch conditions of interest   
As sensory neuron-expressed receptors for pruritic agents, Mrgprs have been 
previously linked to acute itch. However, Mrg receptor involvement in chronic itch 
conditions has not been addressed. Chronic pruritus is a complex and often debilitating 
symptom that accompanies a range of cutaneous and non-cutaneous diseases (Ständer et 
al., 2007; Yosipovitch and Bernhard, 2013a). The most widely known pruritogen is 
histamine, which is secreted by mast cells in the skin and activates histamine receptors on 
nearby sensory neurons (Bautista et al., 2014; Ikoma et al., 2006; LaMotte et al., 2014; 
Yosipovitch and Bernhard, 2013b). While viable treatments exist for histamine-mediated 
itch, most non-histaminergic conditions are more difficult to treat because the mediators 
are often unknown (Kremer et al., 2011). Major causes of clinically relevant non-
histaminergic itch include primary skin disorders, like allergic contact dermatitis, chronic 
kidney disease, and liver and gallbladder disease. In this thesis, I focus primarily on two 
itch conditions: cholestatic pruritus and allergic contact dermatitis. 
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1.3.1 Cholestatic pruritus  
In the United States, hundreds of thousands of patients with cholestasis report 
experiencing a severe, generalized pruritus (itch). Cholestasis, or the slowing or stoppage 
of bile flow, can result from numerous liver and gallbladder diseases. Cholestatic patients 
do not exhibit classic signs of histamine release such as erythema or swelling (Bergasa, 
2014), and cholestatic itch does not respond to histamine receptor antagonists (Bergasa, 
2014; Beuers et al., 2014; Hegade et al., 2016). Instead, the most effective treatments for 
cholestatic itch are physical removal of the causative obstruction when applicable (such 
as in the case of gallstones), draining bile, or a liver transplant (Appleby et al., 2015; 
Hegade et al., 2016; Hofmann and Huet, 2006). Because on the success rate of these 
procedures, the causative pruritogens of cholestatic pruritus are hypothesized to originate 
from bile. Leading candidates include opioids, lysophosphatidic acid, bilirubin, and bile 
acids.  
Endogenous opioids, bile acids, and autotaxin, the enzyme that produces 
lysophosphatidic acid, are upregulated in both cholestatic animal and patient serum 
(Swain et al., 1992; Thornton and Losowsky, 1988, 1989a, b). Opiod and bile acid serum  
levels do not correlate with itch while autotaxin levels have high positive prediction value 
for cholestatic pruritus (Kremer et al., 2012).  In small clinical trials, both opioid 
antagonists and bile acid binding resins have been demonstrated to be effective in 
controlling cholestatic itch (Bergasa, 1998; Bergasa et al., 1998; Bergasa et al., 1992; 
Swain et al., 1992). However, the effectiveness of bile acid binding resins has been 
challenged (Kremer et al., 2010; Kuiper et al., 2010).  
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Cholestasis will often result in jaundice, a yellowing of the skin and eyes that 
occurs due to elevated levels of bilirubin depositing in skin. Bilirubin is a downstream 
metabolite of heme. In cells, heme is broken down by heme oxygenase 1 (HMOX1) to 
biliverdin, which is reduced by biliverdin reductase (BVR) to bilirubin. Bilirubin is 
extremely lipophilic can cross cell membranes. In serum, bilirubin is typically bound to 
albumin. In the liver, bilirubin is conjugated to glucuronic acid by UGT1A*28 to form a 
water-soluble compound. Both conjugated and unconjugated bilirubin are excreted in bile. 
Bilirubin is not thought to play a role in cholestatic pruritus because serum levels of 
bilirubin do not correlate with severity of pruritus in human patients (Bergasa, 2014). 
Furthermore, there are numerous examples of non-pruritic jaundice conditions such as 
Dubin-Johnson and Crigler-Najjar  disease (Strassburg, 2010). At physiologic and mildly 
elevated concentrations (0.2-2.7 mg/dL, 3.4 - 46.2 M), bilirubin is benign and thought to 
have a cardioprotective effect (Bulmer et al., 2013; Vitek et al., 2002). 
1.3.2 Allergic contact dermatitis 
Allergic contact dermatitis (ACD) is a type IV hypersensitivity reaction that 
typically presents as an intensely pruritic, eczematous skin rash that is not amenable to 
antihistamine treatment (Kostner et al., 2017). Disease develops when an organism comes 
in contact with a hapten that combines with skin antigens to promote a dendritic-
cytotoxic T-cell response against skin cells (Kostner et al., 2017). After initial 
sensitization to an exogenous hapten, further contact will elicit a severe dermatologic 
reaction. 
Mast cells have been demonstrated to modulate ACD disease severity via release 
of both pro- and anti-inflammatory cytokines (Askenase et al., 1983; Dudeck et al., 2011; 
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Gimenez-Rivera et al., 2016; Grimbaldeston et al., 2007). In ACD skin, multiple potential 
Mrgprb2 and MRGPRX2, mast cell receptor, agonists, such as neuropeptides, are 
upregulated. Release of cytokines from both mast cells and other immune cells have been 
demonstrated to be involved in ACD-itch, including IL-33 activation of neuronal ST2 
and T-cell release of IL-31 (Liu et al., 2016; Takamori et al., 2018).  
1.4 Thesis goals 
 Mrgprs have been identified as receptors for numerous non-histaminergic 
pruritogens. However, at the time of this thesis’s inception, all previously published 
Mrgpr ligands were non-physiologic molecules, and Mrgpr involvement in clinically 
relevant pathological itch had not been addressed. Based on acute itch studies and 
expression data, I hypothesized that Mrgprs could play a role in mediating chronic itch 
conditions. The goals of my thesis were to test this hypothesis. I was specifically 
interested in cholestasis and ACD due to widespread prevalence and a lack of effective 
treatment. As secondary goals, I was interested in probing the potential interactions 
between mast cells and sensory nerves and also functionally characterizing the recently 
identified mast-cell Mrgprs, b2 and X2. 
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2. Methods 
Group data were expressed as mean ± SEM unless otherwise noted. Two-tailed 
unpaired Student’s t-tests, Two-way ANOVA, Fisher’s exact test, and Chi-squared tests 
were used to determine significance in statistical comparisons, and differences were 
considered significant at P < 0.05. Statistical power analysis was used to justify sample 
size, and variance was determined to be similar among all treatment groups as determined 
by F test unless otherwise noted. No samples or animals subjected to successful 
procedures and/or treatments were excluded from analysis. All behavior experiments 
were designed in a blocked manner with consideration for both genotype and treatment. 
2.1 Experimental animal models 
Mice were housed 2-5 per cage with a 12-hour light/dark cycle and ad 
libitum access to rodent chow and water. Behavior assessments were performed during 
the light phase. All experimental protocols were approved by the Animal Care and Use 
Committee at the Johns Hopkins University School of Medicine (Protocol Number: 
MO16M40). All mice used for this study were born and bred within Hopkins Miller 
Research Building Animal facility and weaned at 3-3.5 weeks of age. Mice used for 
experiments were 1.5-3 months old males and females (20 - 30g) on the C57BL/6 
background unless otherwise noted.  
Mrgpr-clusterΔ-/-, Mrgpra1GFP, MrgprdPLAP, Tg(Mrgpra3-Cre), Tg(Pirt-Cre), 
Mrgprb2-/-,  and Tg(Mrgprb2-Cre) were generated as previously described (Dong et al., 
2001; Liu et al., 2009; 2007; Han et al., 2012; Kim et al., 2014; McNeil et al., 2015). 
Rosa26lslGCaMP6s, Rosa26lsltdTomato, and cKitW-sh (SASH) mice were purchased from 
Jackson Labs. (Kim et al., 2016)Mrgpra1-/- mice were generated using CRISPR-Cas9 on 
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the C57BL/6 background using the following guide RNA sequence: 
TTCCCAGCAGCACCTGTGCA GGG. Blvra -/- mice were generated at Ozgene 
(Australia) on a C57BL/6J background. +X4 humanized mice were generated by crossing 
Tg(Mrgpra3-Cre) mice with newly generated ROSA26lslMRGPRX4 mice (129svJ/Bl6 mixed 
background). ROSA26lslMRGPRX4 mice were generated by homologous recombination of 
an MRGPRX4 cDNA construct under loxp-STOP-loxp control to the ROSA26 locus.  
2.1.1 Behavior 
All applicable behavioral tests were performed and analyzed with the 
experimenter blind to genotype and with littermates if possible. All mice used were 8-12 
week males and females (20 to 30 g). There were no significant differences in itch 
between male and female mice. All itch behavior experiments were performed between 8 
a.m. and 12 p.m. On the day before the experiment, animals were placed in the test 
chamber for 30 minutes before being subjected to a series of three mock injections with 
5-minute break periods in between. On the day of the experiment, animals were first 
allowed to acclimatize to the test chamber for 10 minutes before injection. Pruritic 
compounds were subcutaneously injected into the nape of the neck (50L volume) or 
cheek (10L volume), and scratching behavior was observed for 30 minutes. A bout of 
scratching was defined as a continuous scratching movement with either hindpaw 
directed to the injection site. In the cheek injection model, a wipe was defined as a single 
forepaw stroking the site of the injection. Use of both forepaws on the face or cheek was 
considered as grooming behavior. Scratching behavior was quantified by counting the 
number of scratching bouts at 5 min intervals over the 30-min observation period. Wiping 
was quantified at 2 min intervals over a ten-minute observation period. All 
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pharmacological antagonists were given intraperitoneally thirty minutes prior to injection 
of pruritogen.  
Bilirubin is highly susceptible to oxidation and photolysis. Accordingly, bilirubin 
was freshly prepared just prior to each experiment in either DMSO or 0.1 M NaOH and 
then maintained in the dark. For calcium imaging analyses, bilirubin was diluted into 
calcium imaging buffer a few seconds before use. Final concentration of DMSO in all 
applicable tested solutions was < 0.5%. To maintain the integrity of bilirubin in human 
plasma samples, samples were stored at -80C until use. Plasma stocks were maintained 
in the dark to minimize photolysis during injection or experimental manipulation. Plasma 
bilirubin was evaluated by HPLC as described above. All other drugs were prepared as 
100 l – 1,000 l aliquots and stored at -20C before thawing at 4C. Freeze/thaw cycles 
were avoided whenever possible. To remove microprecipitates, we centrifuged our 
bilirubin solutions at 21,000g for 20 min to ensure that bilirubin was in solution. 
Whenever physiologically and experimentally reasonable, we excluded divalent cations 
in our in vitro biophysical experiments. 
2.1.2 Models of Cholestatic Itch 
1-naphthyl isothiocyanate (ANIT; Sigma) was solubilized in olive oil (Sigma). 
Animals were dosed with 25 mg/kg ANIT per os daily for five days. On day five, animals 
were acclimatized for itch behavior. On day six, animals were placed in test chambers 
and videotaped for one hour. The number of scratching bouts, defined as a continuous 
scratching movement with either hindpaw, was counted and binned in five minute 
intervals during the one hour period. After itch behavior was assessed, animals were 
administered pentobarbital (50 mg/kg, i.p.). Blood was collected by cardiac puncture and 
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placed into heparinized tubes (BD Biosciences). After centrifugation, plasma was 
collected, aliquoted, and stored at -20C until analysis. Bile acid levels were assessed by 
a fluorometric kit from Cell Biolabs. When applicable, mice were then proceeded for 
histology. For QWF antagonism of cholestatic itch, Day 5 ANIT-treated animals were 
dosed with either 1mg/kg QWF dissolved in PBS or PBS vehicle i.v. via tail vein 
injection approximately 10 minutes before behavioral assessment of spontaneous itch.  
The dose was chosen based on previous studies (Azimi et al., 2017) as well as published 
pK data indicating stability in plasma (t1/2 = 70 min). 
2.1.3 Models of allergic contact dermatitis 
For ovalbumin associated itch, we first sensitized animals by injecting 50 μg of 
ovalbumin in phosphate-buffered saline (PBS) with 2 mg of aluminum hydroxide i.p. 10 
days later, animals were re-injected i.p. with 20 μg of ovalbumin in PBS containing 2 mg 
of aluminum hydroxide. After one week, 50 μg of ovalbumin in saline was administer 
and scratching behavior was quantified. Contact dermatitis model was performed by first 
shaving the abdomens of animals the day prior to experimentation. Shaved abdomens 
were treated with 40l of either 3% DNCB, SADBE, or Oxazolone dissolved in acetone: 
olive oil (4:1 v/v) QD for three days. After four days, the nape of the neck of animals 
were shaved. The next day, 1% DNCB, SADBE, or Oxazolone dissolved in acetone: 
olive oil (4:1 v/v) was applied to shaved skin QD for three days. The next day, animals 
were habituated by being placed in the test chamber for 1 hour. The following day, 
behavior was assessed, and skin samples were collected. For skin thickness 
measurements, animals were sensitized with 100l of either 3% DNCB, SADBE, or 
Oxazolone dissolved in acetone: olive oil (4:1 v/v) on shaved abdomen. Five days later, 
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10l of respective agent was applied to each side of the right ear. At the same time, 10l 
of vehicle was applied to each side of the left ear. 24 hours later, ear thickness of both 
right and left ears was assessed with Mitutoyo digimatic calibrator. 
2.2 Human sample collection 
 Plasma from patients suffering from hyperbilirubinemia, specifically cholestasis, 
was isolated under a protocol approved by the Institutional Review Board at the Johns 
Hopkins University School of Medicine (Study number: IRB00154650). Control plasma 
was isolated from donors who did not exhibit kidney or liver disease, had no complaints 
of itch, and were free from any detectable viral infection (HCV, HBV, HIV). Both 
cholestatic and control plasma were isolated under protocols approved by the Institutional 
Review Board at the Johns Hopkins University School of Medicine (Cholestasis Study 
number: IRB00154650; Control study number: NA_00013177, the Johns Hopkins 
Department of Dermatology Patient Database and Tissue Bank). Whole blood was 
collected into PAXgene tubes (PreAnalytiX 761115) and centrifuged for 5 minutes at 
300g. Plasma was then collected, aliquoted, and stored at -20C until experimentation. At 
time of plasma collection, a 5D itch questionnaire was administered.  
De-identified human skin tissues were obtained under IRB-exempt protocols 
through the Division of Dermatology at Washington University School of Medicine and 
the Skin Biology and Diseases Resource-based Center at the Perelman School of 
Medicine at the University of Pennsylvania. Allergic contact dermatitis lesional skin was 
obtained from eleven patients aged 17 - 89. Eight patients were female, and three patients 
were male. Healthy control skin was taken from eight patients aged 29 – 47. All healthy 
skin was collected from female patients. Besides allergic contact dermatitis where 
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indicated, all patients were otherwise healthy. Skin tissue sections from were obtained 
from biopsy specimens that were fixed in 10% neutral buffered formalin and embedded 
in paraffin.  
2.3 In vitro Ca2+ imaging and analysis 
All cultured cells were maintained in DMEM supplemented with 10% FBS and 
1% Penicillin/Streptomycin at 37°C, 5% CO2. All data included were generated from 
cells tested for mycoplasma and found to be negative. Cells were imaged in calcium 
imaging buffer (CIB; 10 mM HEPES, 1.2 mM NaHCO3, 130 mM NaCl, 3 mM KCl, 2.5 
mM CaCl2, 0.6 mM MgCl2, 20 mM glucose, and 20 mM sucrose at pH 7.4 and 290-300 
mOsm). To monitor changes in intracellular [Ca2+] ([Ca2+]i), cells were loaded with either 
Fura 2-AM (HEK293 cells) or Fluo 4-AM (DRG neurons and mast cells) for 30 min in 
the dark at 37°C in CIB just prior to imaging. With Fura 2-AM, emission at 510 nm was 
monitored from excitation at both 340 nm and 380 nm. With Fluo 4-AM, emission at 520 
nm was monitored from excitation at 488 nm. Cells were identified as responding if the 
intracellular [Ca2+] rose by either 50% compared to baseline or 50% compared to the 
[Ca2+]i change assayed during addition of 50 mM KCl (neurons only). Damaged, 
detached, high-baseline, and motion-activated cells were excluded from analysis.  
HEK293 cells  
In initial screens, HEK293 cells stably expressing the murine G-protein alpha-
subunit Gα15, a unique Gα protein that non-selectively couples a large variety of GPCRs to 
phospholipase C 30, were plated on poly-D-lysine-coated coverslips and transiently 
transfected with constructs encoding the MRGRPR of interest. 12-24 h later, cells were 
loaded with the Fura 2-AM. Unless otherwise specified, compounds were perfused into 
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the imaging chamber for approximately thirty seconds after a baseline period was 
established. Response was then monitored at 5 s intervals for an additional 60 s.  
DRG neurons 
DRGs were incubated with Fluo-4 AM 24 hour after dissociation (native 
genotype) or 48 hour after dissociation (virally transduced). Unless otherwise noted, cells 
were imaged for 20 sseconds to establish a baseline before compounds were added. After 
30 s, a 2 min wash was applied before addition of another substances. At the end of every 
imaging trial, 50 mM KCl was added as a positive control. Cells included in calculating 
percentages all displayed at least a 50% increase in [Ca2+]i compared to baseline upon 
addition of KCl. For ruthenium red inhibitor experiments, neurons were incubated with 
10 µM ruthenium red for 5 minutes prior to imaging. Percentage activated was 
determined as earlier described. 
Mast cells  
Mast cells were purified as described and plated onto glass coverslips coated with 
30 mg/mL fibronectin and allowed to recover for 2 h at 37C. Cells were then loaded 
with Fluo-4 AM. 
EC50 and IC50 determinations 
HEK293 cells stably expressing either MRGPRA1, MRGPRX4, and MRGRPC11 
were seeded in poly-D-lysine-coated 96-well plates at 10,000 cells/well. Cells were 
loaded with Fura 2–AM, washed twice, and maintained in CIB. Haem metabolites were 
freshly dissolved in DMSO in dim light and then diluted into a buffer comprised of 20 
mM Tris and 150 mM NaCl at pH 8.8. Potential changes in pH were evaluated prior to 
each experiment. EC50 values were determined from dose-responses performed in 
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triplicate, repeated 2-4 times. To determine potential antagonism by QWF against 
bilirubin, cells were treated with varying doses of QWF for 1 min in CIB prior to 
application of agonist. 
2.4 In vivo DRG Ca2+ imaging 
DRG exposure surgery was performed as previously described (Kim et al., 2014). 
Throughout the surgery, mice were kept on a heating pad (DC temperature controller, 
FHC) to maintain body temperature at 37C ± 0.5C as monitored by rectal probe. Mice 
were anesthetized by i.p. injection of sodium pentobarbital (40 mg/kg) and their backs 
were shaved and disinfected. Ophthalmic ointment (Lacrilube; Allergen Pharmaceuticals) 
was then applied. An approximately 2-cm midline incision was made at the lower part of 
the lumbar enlargement and 0.1 mL of 1% lidocaine was injected into the paravertebral 
muscles before they were dissected away to expose L3–L5 vertebrae. Using rongeurs, the 
surface aspect of the L4 DRG transverse process was removed and the underlying DRG 
was exposed. Bleeding was stopped using styptic cotton.  
In vivo imaging of whole L4 DRG was performed for 1–3 hours immediately 
following surgery. Images were acquired using a laser-scanning confocal microscope 
(Leica LSI microscope) equipped with a 53 0.5 NA macro dry objective and fast EM-
CCD camera. Live images were acquired at 8 to 10 frames in frame-scan mode per 7–8 
seconds, at depths of 0 to 70 mm below the dura with the DRG in the focal plane. 
Throughout imaging, body temperature was maintained at 37C ± 0.5C with a heating 
pad and rectal temperature monitoring. Anesthesia was maintained with 2% isofluorane 
and pure oxygen delivered through nosecone. Mice were laid abdomen-down on a 
custom-designed microscope stage. The spinal column was secured at two sites using 
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clamps. Imaging was monitored during the activation of DRG neuron cell bodies by 
peripheral stimuli (5l of the stated concentration of either mast cell or neuronal 
activators) delivered via Hamilton syringe.  
For imaging data analysis, raw image stacks were collected, deconvoluted, and 
imported into ImageJ (NIH). Optical planes from sequential time points were re-aligned 
and motion corrected using the stackreg rigid-body cross-correlation-based image 
alignment plugin. The number of counted activated neurons between different mice and 
different DRG imaging periods was normalized to the total number of neurons present in 
the DRG. The total number was counted using the thresholding function in ImageJ 
software from a high-quality, Z-stack image of DRG at baseline. The size of activated 
neurons was calculated using the area function in ImageJ. 
Calcium signaling amplitudes were normalized Ft /F0 as a function of time. F0 was 
defined as the average pixel intensity during the first two to six frames of each imaging 
experiment. Changes in fluorescence were measured from all neurons that displayed a 
change from baseline and selected for further analysis. In subsequent analysis, neurons 
that displayed < 0.2 F0 change in baseline, were only active during the injection period, 
and displayed a > 0.2 F0 change during either the baseline or the saline imaging periods 
were excluded from analysis. The peak area was measured using the area under the curve 
(AUC) functionality in GraphPad PRISM.  Signal peaks were defined as a >0.2F0 
increase over baseline followed by either a return to baseline  10% or normalization of 
signal by >0.2F0. Shoulder peaks were defined as those peaks that occur before both a 
return from peak to baseline ± 10% F0 and before normalization of signal by >0.2F0 and 
were excluded from analysis. There is significant activation associated with injection into 
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the paw. In determining whether a neuron was activated within an imaging window, the 
neuron, represented by its designated region of interest (ROI) needed to exhibit multiple 
peaks of > 0.2F0 from baseline outside of the first minute after injection. All putative 
responding cells and counted peaks included in analysis were verified visually using the 
raw imaging data and individual neuron calcium traces. The average Ft /F0 values for 
specific ROIs were tested for statistical significance by repeated measures ANOVA, 
followed by Mann-Whitney statistics. Fiji (NIH), LIF (Leica), and PRISM software were 
used to analyze and plot Ca2+ imaging data. 
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3. Results 
3.1 Identification of a bilirubin receptor that may mediate a component of 
cholestatic itch (text adapted from Meixiong, Vasavda et al., eLife 2019) 
Despite the long-standing association between jaundice and pruritus (Talwalkar et 
al., 2003), bilirubin itself has not been tested as a pruritogen. To determine whether 
bilirubin elicits pruritus, I subcutaneously injected bilirubin into the napes of mice. 
Pathophysiologic concentrations of bilirubin stimulated scratching in a dose-dependent 
manner at the site of injection (Figure 1A).  Pre-incubating bilirubin with excess human 
serum albumin, which binds bilirubin with high affinity (Breaven et al., 1973; Griffiths et 
al., 1975; Jacobsen and Broderson, 1983), elicited fewer scratches (Figure 1A). The 
behavioral profile of bilirubin-induced scratching mirrored that of two well-characterized 
pruritogens, histamine and chloroquine (Figure 1B). Notably, histamine and chloroquine 
only elicit itch when injected into mice at millimolar concentrations despite having 
nanomolar affinity towards their receptors. In comparison, bilirubin elicited a similar 
degree of itch even when injected at lower concentrations than histamine or chloroquine 
(Figure 1B). Since mice indiscriminately scratch if injected at the nape with substances 
that trigger either itch or pain, we also injected mice at the cheek. Unlike at the nape, 
painful sensations at the cheek evoke a distinct wiping  behavior instead of scratching, 
whereas itchy sensations still elicit scratching (Shimada and LaMotte, 2008). Injecting 
bilirubin in the cheek prompted dose- 
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Figure 1. Bilirubin elicits non-histaminergic, Mrgpr-dependent pruritus. (A) Scratching 
bouts associated with injection of bilirubin. The indicated amount of bilirubin was injected into 
the nape of mice. The blue bar (+HSA) represents animals injected with 60 µg bilirubin pre-
incubated with 1% human serum albumin. Veh n=8; 6 µg n=5, 18 µg n=11, 30 µg n=12, 60 µg 
n= 7, +HSA n=12. (B) Time course of itch behavior associated with bilirubin, histamine, or 
chloroquine. Scratching bouts were binned according to 5-minute intervals. Bilirubin n=16, 
Histamine n= 13, Chloroquine n=11. (C) 60 µg bilirubin was injected into the nape of WT and 
Mrgpr-cluster KO littermates. WT n=8, Mrgpr-cluster KO n= 13. (D) 60 µg of the indicated 
metabolite was injected into WT and Mrgpr-cluster KO littermates. Hemin (WT n=10, Mrgpr-
cluster KO n=6), Biliverdin (WT n= 7, Mrgpr-cluster KO n= 7), Urobilinogen (WT n=15, Mrgpr-
cluster KO n=8), Stercobilin (WT n=7, Mrgpr-cluster KO n=5). (E) The pathway of heme
degradation. The skeletal formula of each metabolite is depicted above its optimal 3D 
geometry, as calculated by a B3LYP functional and 6-31G(d) basis set. Blue and orange 
represent orbital parity of each metabolite’s HOMO obtained from DFT calculations. (A, C, D)
Mean ± s.e.m. depicted. Each open circle represents an individual mouse. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; two-tailed unpaired Student’s t-test. 
dependent scratching just as it did at the nape (Figure 2A). Bilirubin elicited neither 
wiping nor licking, indicating that it selectively triggers itch and not pain (Figure 2B-C).  
We injected mice with similarly structured metabolites to determine the 
specificity of bilirubin’s pruritic activity (Figure 1E). The two metabolites directly 
epistatic to bilirubin, hemin and biliverdin, did not induce scratching despite also being 
tetrapyrroles (Figure 1D). While hemin, biliverdin, and bilirubin display only minor 
atomic and electronic differences between them, they vary substantially in their 
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physiochemical properties and structures (Figure 1E). To better understand these 
differences, we performed density functional theory (DFT) calculations (Becke, 1993; 
Hohenberg and Kohn, 1964; Kohn and Sham, 1965; Stephens et al., 1994) followed by 

































































































































Figure 2. Bilirubin elicits non-histaminergic pruritus and not pain. (A) Scratching bouts 
associated with cheek injection of bilirubin. The indicated amount of bilirubin was injected in a 
10 µl volume and the number of scratching bouts was assessed for 30 min. Vehicle n=6, 1.8 
µg n=5, 3 µg n=4, 6 µg n=5, 6 µg (Mrgpr-clusterΔ−/−) n= 6. (B) Wiping associated with injection 
of 6 µg bilirubin into the cheek. Wipes were assessed for 10 min post-injection, vehicle n= 5, 
bilirubin n=7. (C) Lick time associated with injection of 6µg bilirubin into the paw. Licking was 
assessed for 10 min post-injection. n=3 per condition. (D) H1 blocker does not inhibit bilirubin-
induced pruritus. Either vehicle or 30 mg/kg Cetirizine was given i.p. 30 min prior to injection of 
bilirubin at the nape of the neck. Scratching bouts were assessed for 30 min post-injection. 
Vehicle n= 10, Cetirizine n = 5. (E) Mast cell histamine release in response to 100 µM bilirubin. 
Vehicle for Compound 48/80 n=4, Compound 48/80 (10 µg/mL) n=4, Vehicle n=6, Bilirubin 
n=8. (F) Ca2+ imaging of murine peritoneal mast cells. After a 10s baseline, 100 µM bilirubin 
was added. 15s later, a 1min wash was applied before addition of 10µg/mL compound 48/80. 
Drugs were applied when indicated by the black bars. Mean ±95% CI depicted. n=26. (A-E) 
Mean plus s.e.m. depicted. Open circles represent independent data points. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; two-tailed unpaired Student’s t-test. n.s., not significant. 
 
single point energy calculations to determine the optimal geometry of each metabolite. 
Unlike in heme and biliverdin, bilirubin’s four pyrroles are extended and do not lie in the 
same plane (Figure 1E). DFT calculations revealed that urobilinogen and stercobilin, two 
bacterial metabolites derived from bilirubin, adopt a similar extended conformation. Both 
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urobilinogen and stercobilin were able to stimulate scratching behavior (Figure 1D), 
indicating that bilirubin’s non-polar pyrroles may be important for its pruritic activity. 
Patients with jaundice-associated pruritus receive little benefit from 
antihistamines (Carstens et al., 2014). Consistent with these clinical findings, the 
histamine receptor 1 blocker cetirizine (30 mg/kg, i.p.) failed to alleviate scratching 
behavior in mice injected with bilirubin (Figure 2D). Furthermore, bilirubin did not elicit 
a calcium response or induce appreciable histamine release from peritoneal mast cells 
(Figure 2E-F). 
The Mas-related G-protein coupled receptor (Mrgpr) family of receptors is a 
major mediator of non-histaminergic pruritus (Han et al., 2012; Liu et al., 2012; 2009; 
Sikand et al., 2011). To test whether Mrgprs mediate bilirubin-induced pruritus, we 
injected mice lacking a cluster of 12 Mrgpr genes (Mrgpr-clusterΔ−/− or Mrgpr-cluster 
KO) with bilirubin (Liu et al., 2009). Mrgpr-cluster KO animals scratched approximately 
75% less than wild type (WT) mice, indicating that one or more of the 12 Mrgprs within 
the cluster mediates bilirubin-induced pruritus (Figure 1C).  
To identify which Mrgpr is sensitive to bilirubin, we individually expressed each 
of the 12 Mrgprs deleted in the Mrgpr-cluster KO mouse in human embryonic kidney 
(HEK) 293 cells and monitored changes in intracellular calcium upon applying bilirubin. 
To ensure we would observe a calcium response following a true ligand-receptor 
interaction, we expressed the receptors in HEK293 cells stably expressing the G-protein 
alpha-subunit Gα15, a Gα protein that couples GPCRs to intracellular calcium stores via 
phospholipase C (PLC). 
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Among the twelve cell lines expressing an Mrgpr, only MRGPRA1-expressing 
cells exhibited a calcium response to bilirubin (EC50 of 145.9 µM [96, 220]) (Figure 3A, 
D). The same cells that responded to bilirubin also responded to FMRF, an MRGPRA1 
Figure 3. Bilirubin activates murine MRGPRA1 and human MRGPRX4. Ca2+ imaging and 
transformed binding isotherms of HEK293 cells stably expressing MRGPRA1 (A-E) or 
MRGPRX4 (F-J). (A-C, F-H) 50 µM bilirubin was added where indicated by black bars. After 
15 s, a 1 min wash was applied. Mean ±95% confidence interval (CI) depicted. n=10. In (A) 30 
µM FMRF was added after washing as indicated by the black bar. In (B-C) and (G-H), cells 
were pre-incubated with either 10 µM of the PLC inhibitor U73122 or 10 µM of the Gαq inhibitor 
YM254890 for 30 min prior to imaging. Concentration–Ca2+ response curves of bilirubin, 
conjugated bilirubin, and hemin towards (D) MRGPRA1, (I) MRGPRX4, and (N) MRGPRC11 
and BAM8-22 towards MRGPRC11, an established peptide ligand. Data are a representative 
experiment of 3 independent replicates performed in triplicate, depicted as mean ± s.e.m.
Transformed binding isotherms for bilirubin, conjugated bilirubin, and hemin to (E) MRGPRA1, 
(J) MRGPRX4, and (O) MRGPRC11 and BAM8-22 to MRGPRC11. Data are an average of 3 
independent experiments, depicted as mean ±s.e.m. (K) Bilirubin-stimulated G-protein activity 
of partially-purified MRGPRA1, MRGPRX4, and MRGPRC11 membrane complexes. 
[35S]GTPγS binding was measured in the presence of 0.5% DMSO or 50 μM bilirubin. Mean ±
s.e.m. depicted. **, P < 0.01; two-tailed unpaired Student’s t-test. (L) Scratching bouts from 
injection of 60 µg of bilirubin in WT and A1 KO animals. WT n=10, A1 KO n=12. (M) Scratching 
bouts from injection of 60 µg of FMRF in WT and A1 KO animals. WT n=8, A1 KO n=7.  (L-M) 
Mean ± s.e.m. depicted. Open circles represent individual mice. *, P < 0.05 by two-tailed 
unpaired Student’s t-test.
agonist (Dong et al., 2001). To ensure that bilirubin initiated signaling at MRGPRA1 and 
not downstream, we pre-treated MRGPRA1-expressing cells with inhibitors of GPCR 
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signaling: the PLC inhibitor U73122 or the Gq inhibitor YM-254890. Both compounds 
abolished bilirubin-induced calcium responses (Figure 3B-C).  
In addition to bilirubin, glucuronidated bilirubin is often upregulated in jaundice-
associated itch. We assessed whether ditaurate bilirubin, a distinct but similar bilirubin 
derivative, could activate MRGPRA1. Indeed, ditaurate bilirubin activated MRGPRA1-
expressing cells (Figure 3D). Hemin failed to activate MRGPRA1 (Figure 3D), 
consistent with our earlier behavioral findings in which hemin did not evoke scratching. 
No other Mrgpr among the 12 that we screened responded to bilirubin (Figure 4). 
Figure 4. Bilirubin does not activate other itch-associated Mrgprs. (A-E)
Ca2+ imaging of HEK293 cells transiently expressing (A) MRGPRA3, (B) 
MRGPRC11, (C) MRGPRD, (D) MRGPRX1, or (E) MRGPRX2. 50 µM bilirubin 
was added where indicated by black bars. After fifteen seconds, a one minute 
wash was applied. After washing, either (A) 1 mM chloroquine, (B) 3 µM 
BAM8-22, (C) 1 mM β-alanine, (D) 3 µM BAM8-22, or (E) 10 µg/mL compound 
48/80 was added as indicated by black bars. Mean ± 95% CI depicted. n=10.
 
The human MRGPRX family of receptors has functional similarities between 
species but have no obvious structural homologs in rodents (Solinski et al., 2014; Zylka 
et al., 2003). The mouse Mrgpra family is closest in sequence homology to the human 
MRGPRX family (Dong et al., 2001; Lembo et al., 2002; Zhang et al., 2005). Of the four 
human MRGPRX receptors, only MRGPRX4-expressing cells responded to bilirubin 
(EC50 of 61.9 µM [44, 87]) (Figure 3F, I). U73122 and YM-254890 inhibited bilirubin-
induced calcium responses in MRGPRX4-expressing cells just as with MRGPRA1 
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(Figure 3G-H). Conjugated bilirubin also activated MRGPRX4, whereas hemin had no 
effect (Figure 3I). 
To confirm that bilirubin directly binds the identified receptors, we assayed 
thermophoresis of each receptor in the presence and absence of bilirubin. Thermophoresis 
of a molecule is affected by physical parameters such as size, charge, and solvation. By 
extension, the thermophoresis of one molecule is altered when it interacts with another, 
and can therefore be used to measure interactions between molecules (Duhr and Braun, 
2006). Using this approach, we determined that bilirubin bound MRGPRA1 with a KD of 
92.9 ± 15 µM and MRGPRX4 with a KD of 54.4 ± 13 µM (Figure 3E, J). Bilirubin 
exhibited little to no affinity for the closely related BAM8-22 receptor MRGPRC11 
(Figure 3O). Hemin, which did not activate MRGPRA1 or MRGPRX4 by calcium 
imaging (Figure 3D, I), also did not bind MRGPRA1 or MRGPRX4 (Figure 3E, J). 
Conjugated bilirubin bound both MRGPRA1 and MRGPRX4, although with a lower 
affinity than unconjugated bilirubin (Figure 3E, J). To make certain that bilirubin 
activates MRGPRA1 and MRGPRX4 upon binding, we measured exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP), one of the first events in GPCR 
signaling. Bilirubin increased GTP binding to MRGPRA1 and MRGPRX4 membrane 
complexes, but not to MRGPRC11 (Figure 3K). To confirm that bilirubin activates 
MRGPRA1 in vivo to trigger itch, we generated an Mrgpra1 (A1 KO) knockout mouse 
line using CRISPR-Cas9 (Jinek et al., 2012) (Figure 5). A1 KO animals scratched 
significantly less than WT mice after exposure to either bilirubin or the established 
agonist FMRF, demonstrating that Mrgpra1 is functional in adult mice (Figure 3L-M). 
The KD of bilirubin towards MRGPRA1 and MRGPRX4 suggests that bilirubin likely 
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does not interact with these receptors in healthy individuals. Additional ligands with 
nanomolar affinities towards MRGPRA1 or MRGPRX4 may exist that modulate the 








Figure 5. CRISPR deletion of 
MRGPRA1. (A) Comparison of WT 
and A1 KO genomic sequences. 
Location of 2 base pair (bp) deletion 
shown by dashes. Numbers 
correspond to MRGPRA1 open 
reading frame. (B) Sequencing data 
depicting the 2 bp deletion. (C) A 
translation of the open reading frame 
of MRGPRA1 KO beginning with the 
start codon. The 2 bp deletion creates 
a frameshift which results in early 
termination, marked by a red asterisk.
 
We reasoned that if bilirubin triggers itch through MRGPRA1 and MRGPRX4, 
bilirubin should activate these receptors in sensory itch neurons. Previous studies have 
demonstrated that both Mrgpra1 and MRGPRX4 are expressed in sensory neurons within 
the dorsal root ganglia (DRG) (Dong et al., 2001; Flegel et al., 2015; Lembo et al., 2002). 
Mrgpra1 is expressed in a subset of adult DRG and trigeminal ganglia (TG) sensory 
neurons that innervate the skin and ramify in lamina I and II of the spinal cord (Figure 
6A-D). Bilirubin elicited robust action potentials in small-diameter (< 30 µm) WT DRG 
sensory neurons at a proportion consistent with the percentage of sensory neurons that 
encode itch (5 of 50). Bilirubin failed to elicit action potentials in A1 KO neurons (0 of 
60), suggesting bilirubin activates sensory neurons through MRGPRA1 (Figure 6E).  
    
 























































































































Figure 6. Bilirubin activates sensory neurons in an MRGPR-dependent manner. (A-D) 
Confocal microscopy immunofluorescence images of adult mouse tissue sections from 
Mrgpra1GFP animals with GFP expression under the control of the endogenous Mrgpra1 locus. 
(A) Mrgpra1 expression in dorsal root ganglia. Green depicts Mrgpra1GFP. Red depicts anti-
PLAP antibody staining where PLAP expression is controlled by the endogenous Mrgprd locus 
(MrgprdPLAP). Blue depicts antibody staining against calcitonin gene-related peptide (CGRP). 
Scale bar is 50 µM. (B) Trigeminal ganglia (TG) stained with Mrgpra1GFP (green) and anti-
Substance P antibody (red). Scale bar is 50 μm. (C) Back skin stained with anti-GFP antibody 
(green) to visualize Mrgpra1GFP nerve fibers in the dermis. Blue represents DAPI counterstain. 
Scale bar is 50 μm. (D) Spinal cord (SC) (lamina 1 and 2) stained with anti-GFP and IB4-564. 
Mrgpra1GFP (green) staining was found in lamina 2 along with IB4 (red) positive terminals. 
Scale bar is 100 μm. (E) Representative whole-cell current-clamp recording of either WT or A1 
KO DRG neurons. In WT DRG, bilirubin elicited action potentials in 5 out of 50 small-diameter 
neurons. In A1 KO DRG, bilirubin elicited action potentials in 0 out of 60 small-diameter 
neurons. Fisher’s exact test P < 0.05. (F) Histogram of bilirubin-activated neuronal soma 
diameter. (G) Ca2+ imaging of WT DRG neurons. Mean ±95% CI depicted. Compounds 
applied where indicated by black bars. After a 10 s baseline, 50 µM bilirubin was added. 50 
mM KCl was added at the end of each trial. n=20 neurons. (H) Percent activation of WT, A1 
KO, and Mrgpr-cluster KO DRG by vehicle and 50 µM bilirubin. *, P < 0.05; **, P < 0.01; ***, P
< 0.001; Chi-squared test. A neuron was considered to be activated if ∆F > 0.2 for at a least 30 
s. (I) Ca2+ imaging of Mrgpr-cluster KO DRG neurons 48 hrs after either mock infection with 
lentivirus (n=10) or infected with lentivirus encoding Mrgpra1 (n=6), MRGPRX4 (n=10), or 
MRGPRX3 (n=20). 50 µM bilirubin was added when indicated by the black bar. After 20 s, a 1 
min wash was applied before addition of 50 mM KCl. Compounds applied where indicated by 
black bars. Mean ± 95% CI depicted. n=10 neurons. (J) Percent activation of uninfected, 
Mrgpra1-infected, MRGPRX4-infected, and MRGPRX3-infected Cluster -/- neurons by 
bilirubin. ***, P < 0.001. Chi-squared test.
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Bilirubin-sensitive neurons had an average somal diameter of 20.4 ± 1.3 µm, a diameter 
characteristic of itch sensory neurons (Figure 6F). Applying bilirubin to neurons elicited 
calcium transients in approximately 5% of WT DRG neurons (Figure 6G), whereas 
significantly fewer sensory neurons from either Mrgpr-cluster KO or A1 KO mice 
responded (Figure 6H). We sought to determine whether expression of either 
MRGPRA1 or MRGPRX4 was sufficient to render neurons sensitive to bilirubin. To 
address this question, we infected Mrgpr-cluster KO DRGs with lentivirus carrying either 
Mrgpra1, MRGPRX4, or MRGPRX3. Bilirubin activated 14% of Mrgpra1-and 32% of 
MRGPRX4-transduced Mrgpr-cluster KO DRGs (Figure 6I-J). Mrgpr-cluster KO DRGs 
infected with the control gene MRGPRX3 did not respond to bilirubin.   
Bilirubin-responsive neurons partially overlapped with neurons that responded to 
1mM chloroquine, a ligand for MRGPRA3 that typifies itch sensory neurons (Han et al., 
2012) (Figure 7A-C). To validate that bilirubin activates MRGPRA3-positive itch 
neurons, we performed calcium imaging on DRG neurons isolated from Tg(Mrgpra3-
Cre);lsl-tdTomato mice, which express the fluorescent protein tdTomato in Mrgpra3-
expressing neurons. Bilirubin activated a substantial percentage of tdTomato-positive 
neurons (Figure 7D). To confirm that bilirubin activates sensory neurons in vivo, we 
injected 5L of vehicle or bilirubin into paws of Tg(Pirt-Cre);lsl-GCaMP6s mice, which 
express the fluorescent calcium reporter GCaMP6s in DRG sensory neurons (Kim et al., 
2014). Bilirubin, but not vehicle, activated numerous DRG sensory neurons in the paws 
of GCaMP6s mice (Figure 7E). Inhibiting transient receptor potential (TRP) and other 
Ca2+ channels with ruthenium red prevented bilirubin from activating sensory neurons 
(Figure 7F-G) (Imamachi et al., 2009; Liu et al., 2009; Roberson et al., 2013).  
    
 










































































































Total = 541 
Figure 7. Bilirubin activates a population of small-diameter, chloroquine-sensitive 
sensory neurons in a TRP channel dependent mechanism. (A) A representative whole-cell 
current-clamp recording of a WT DRG neuron responsive to addition of both 50 µM bilirubin 
and 1mM chloroquine (CQ). (B) Ca2+ imaging of WT DRG neurons. Mean ±95% CI depicted. 
Compounds applied where indicated by black bars. After a 10 s baseline, 50 µM bilirubin was 
added. After 20 s, a 3 min wash was applied before 1 mM chloroquine was added. After 15 s, 
50 mM KCl was added. n=10 neurons. (C) Venn diagram of total neurons activated by either 
bilirubin and/or chloroquine (Bilirubin alone=7, Chloroquine= 40, Overlap= 13). (D) Percent 
activation of Tg(Mrgpra3-Cre);lsl-tdTomato neurons as assessed by calcium imaging with 
vehicle, 1 mM Chloroquine, or 50 µM bilirubin. (E) In vivo Ca2+ imaging of Pirt-Cre; lsl-
GCaMP6s animals. Briefly, a surgery was performed to expose L4 DRG. Baseline 
measurements were taken before a vehicle injection in ipsilateral paw and subsequent 
injection of 5μL of 100μM bilirubin. Depicted is a representative Ca2+ imaging trace of bilirubin-
activated neurons, n=20, identified by post hoc imaging analysis. The black trace is the mean 
Ft/F0 and red dotted lines represent 95% confidence intervals. (F) Neurons were incubated 
with 10 µM ruthenium red for 10 min before application of 50 µM bilirubin. (G) Percent 
activation of WT neurons, incubated with either vehicle or 10 µM ruthenium red, by 50 µM 
bilirubin. 
 
We wondered whether chronic elevation of bilirubin in vivo, like in cholestasis, 
stimulates Mrgpr-dependent itch. Bile is the primary means by which bilirubin is 
excreted, and patients with cholestasis exhibit elevated levels of bilirubin and other 
pruritogenic substances in their blood (Alemi et al., 2013). To induce hyperbilirubinemia 
and model intrahepatic cholestasis, we administered -napthyl isothiocyanate (ANIT) to 
mice (Eliakim et al., 1959).  We treated WT, Mrgpr-clusterΔ−/−, and A1 KO animals with 
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Figure 8. MrgprA1 KO, Mrgpr-clusterΔ−/−, and BVR KO animals exhibit decreased 
cholestatic pruritus. (A) Experimental flowchart for ANIT model of cholestasis. (B) Scratching 
bouts for vehicle and ANIT-treated mice among WT, Mrgpr-clusterΔ−/−, and A1 KO groups. 
Bouts were assessed in a 30 min period. For the vehicle cohort: WT n=15, Mrgpr-cluster KO 
n=6, A1 KO n=6. For ANIT cohort: WT n=20, Mrgpr-cluster KO n=14, A1 KO n=14.  (C) 
Scratching bouts for vehicle and ANIT-treated animals among WT and BVR KO groups. Bouts 
were assessed in a 30 min period. For the vehicle cohort: WT n=5 and BVR KO n=8. For ANIT 
cohort: WT n=21 and BVR KO n=20. (D) Plasma bilirubin levels (mg/dL) from WT and Mrgpr-
cluster KO ANIT-treated and vehicle-treated animals. For the vehicle cohort: WT n=14, Mrgpr-
cluster KO n=6. For the ANIT cohort: WT n=21, Mrgpr-cluster KO n=17. (E) Plasma bile acid 
levels (µM) from ANIT-treated and vehicle-treated animals. For the vehicle cohort: WT n=4, 
Mrgpr-cluster KO n=5, BVR KO n=5. For the ANIT cohort: WT n=10, Mrgpr-cluster KO n=7, 
BVR KO n=14. (F) Experimental flowchart for Cyclosporin A model of cholestasis. (G) 
Scratching bouts for vehicle and Cyclosporin A-treated WT and A1 KO animals. For the vehicle 
cohort: n=5 for all. For Cyclosporin A cohort: WT n=10 and A1 KO n=8. (H) Scratching bouts 
from vehicle and Cyclosporin A treated WT and BVR KO animals. For the vehicle cohort: n=5. 
For Cyclosporin A cohort: WT n=11 and BVR KO n=7.  (I) Correlation of serum bilirubin levels 
from cholestatic animals and scratching bouts. Line of best fit: Y = 0.23 (X) + 28.78. (J) 
Correlation of skin bilirubin levels from cholestatic animals and scratching bouts. Line of best 
fit: Y = 12.34 (X) + 16.7. (K) Correlation of skin and serum bilirubin levels from cholestatic 
animals. Line of best fit: Y = 7.015(X) – 14.52. (A-H) Mean ± s.e.m. depicted. Open circles 
represent individual data points. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired two-tailed 
Student’s t-test. 
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Mrgpr-clusterΔ−/−, and A1 KO animals exhibited equivalently severe hepatocellular 
injury judged by increases in plasma bilirubin, bile acids, alkaline phosphatase (ALP), 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl 



























































































































































Figure 9. Plasma levels of pathological markers of liver injury are similar between WT, Mrgpr-
clusterΔ−/−, A1 KO, and BVR KO animals. (A) Plasma alkaline phosphatase (ALP) levels among vehicle 
and ANIT-treated animals. For vehicle cohort: WT n=10, Mrgpr-cluster KO n=4, A1 KO n=4, BVR KO n=6. 
For ANIT cohort: WT n=17, Mrgpr-cluster KO n=6, A1 KO n=5, BVR KO n=15. (B) Plasma aspartate 
aminotransferase (AST) levels among vehicle and ANIT-treated animals. For vehicle cohort: WT n=10, 
Mrgpr-cluster KO n=4, A1 KO n=4, BVR KO n=9. For ANIT cohort: WT n=12, Mrgpr-cluster KO n=6, A1 
KO n=5, BVR KO n=17. (C) Alanine aminotransferase (ALT) levels among vehicle and ANIT-treated 
animals. For vehicle cohort: WT n=10, Mrgpr-cluster KO n=4, A1 KO n=4, BVR KO n=6. For ANIT cohort: 
WT n=15, Mrgpr-cluster KO n=6, A1 KO n=5, BVR KO n=17. (D) Gamma-glutamyl transferase (GGT) 
levels among vehicle and ANIT-treated animals. For vehicle cohort: WT n=10, Mrgpr-cluster KO n=4, 
BVR KO n=6. For ANIT cohort: WT n=17, Mrgpr-cluster KO n=6, BVR KO n=15. (E) Met-enkephalin 
levels among plasma from vehicle and ANIT-treated animals. For vehicle cohort: WT n=4, Mrgpr-cluster 
KO and BVR KO n=5. For ANIT cohort: WT n=19, Mrgpr-cluster KO n=10, BVR KO n=11. (F) Autotaxin
activity among plasma from vehicle and ANIT-treated animals. For vehicle cohort: WT and BVR KO n=4, 
Mrgpr-cluster KO n=5. For ANIT cohort: WT n=12, Mrgpr-cluster KO n=8, BVR KO n=10. (A-F) Mean ±
s.e.m. depicted. Open circles represent independent data points. *, P < 0.05; **, P < 0.01, ***, P < 0.001; 
two-tailed unpaired Student’s t-test. n.s., not significant.
 
As expected, ANIT treatment significantly increased pruritus in all animals 
(Figure 8B). However, Mrgpr-cluster KO and A1 KO mice scratched markedly less than 
WT mice (Figure 8B), suggesting that MRGPRA1 mediates a component of 
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hepatobiliary pruritus. In humans, bile acids, endogenous opioids, and LPA are often 
increased in cholestatic sera and have been shown to mediate pruritus (Alemi et al., 2013; 
Bergasa et al., 1998; 1992; Kremer et al., 2010). The serum of ANIT-treated animals 
exhibited elevated bilirubin and bile acids (Figure 8D-E), whereas neither the 
endogenous opioid peptide met-enkephalin (Thornton and Losowsky, 1989a; 1989b) nor 
the LPA-producing enzyme autotaxin were elevated (Figure 9E-F). To assess whether 
other cholestatic pruritogens act at MRGPRs in mice, we injected WT and Mrgpr-cluster 
KO with deoxycholic acid (a bile acid), opiates, and LPA. These other cholestatic 
pruritogens elicited equivalent degrees of scratching in WT and Mrgpr-cluster KO 







Figure 10. Mrgpr-cluster KO animals have intact itch to other cholestatic pruritogens 
and bilirubin synergism with chloroquine itch. (A) Scratching bouts to 1.3mM deoxycholic 
acid (DCA) injected into cheek. WT n = 9, Mrgpr-cluster KO n=9. (B) Scratching bouts to 4 mM
lysophosphatidic acid (LPA) injected into cheek. WT n = 6, Mrgpr-clusterΔ−/−n=6. (C) 
Scratching bouts to 25µg of morphine injected into back. WT n = 7, Mrgpr-clusterΔ−/−n=8. (D) 
Scratching bouts to 25µg of DAMGO injected into back. WT n = 5, Mrgpr-cluster KO n=5. (E)
Synergism of bilirubin with chloroquine pruritus. Scratching bouts to 1mM chloroquine plus 
either vehicle or 500µM bilirubin injected into back. For 1mM chloroquine plus vehicle: WT n = 
9, A1 KO n=5. For 1mM chloroquine plus 500µM bilirubin: WT n = 11, A1 KO n=5. (A-E) Mean 
± s.e.m. depicted. Open circles represent independent data points. **, P < 0.01, ***, P < 0.001; 
two-tailed unpaired Student’s t-test. n.s., not significant.
remain multiple bile acids, LPA molecules, and opiates which remain untested and could 
be agonists against Mrgprs. Based on this data, we hypothesized that Mrgpr-cluster KO 
and A1 KO mice scratched less with ANIT because MRGPRA1 mediates bilirubin-
induced itch. 
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To determine whether bilirubin is activating MRGPRA1 to stimulate itch in 
cholestasis, we induced cholestasis in a mouse that lacks the biosynthetic enzyme for 
bilirubin, biliverdin reductase (BVR KO) (Kutty and Maines, 1981) (Figure 1E, Figure 



































































































































Figure 11. BVR KO and A1 KO animals have intact itch circuits. (A) Quantitative PCR 
analysis of BLVRA transcript from whole brain of WT and BVR KO mice. (B) Representative 
chromatogram of HPLC analysis of plasma from WT and BVR KO mice separated via a C18 
column and analysed by absorbance at 450 nm. C. HPLC chromatogram of plasma from a WT 
mouse spiked with excess bilirubin. (D) Total bilirubin levels from plasma of WT and BVR KO 
animals. WT n=7, BVR KO n=6. (E) Scratching bouts to 150 µg (50 µL of 10 mM) of 
chloroquine. After chloroquine injection, scratching bouts were assessed in a 30-minute period. 
WT n=9, BVR KO n=5, A1 KO n=6. (F) Scratching bouts to 60 µg (100 µL of 1 mM) of 
bilirubin. After bilirubin injection, scratching bouts were assessed in a 30 min period. WT n=8, 
BVR KO n=9. (D-F) Mean plus S.E.M. depicted. Open circles represent independent data 
points. **, P < 0.01 by student’s t-test. n.s., not significant.
BVR KO mice do not have detectable levels of bilirubin in plasma (Figure 11B-D). 
When treated with ANIT, BVR KO mice scratched significantly less than WT mice 
(Figure 8C). Plasma levels of bile acids, ALP, AST, ALT, GGT, met-enkephaline, and 
autotaxin were indistinguishable between treated BVR KO animals and WT controls 
(Figure 9A-D). The diminished response to ANIT is not due to aberrant itch circuits, as 
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BVR KO mice scratched normally when injected with either chloroquine or exogenous 
bilirubin (Figure 11E-F).  
To confirm that the observed differences in cholestatic pruritus were not just 
specific to ANIT, we administered the hepatotoxin cyclosporin A to WT, A1 KO, and 
BVR KO mice (Laupacis et al., 1981). We treated mice with either 50 mg/kg cyclosporin 
A or vehicle for eight days before assessing spontaneous itch (Figure 8F). Cyclosporin A 
induced spontaneous itch in WT animals, whereas A1 KO and BVR KO mice again 
scratched significantly less than WT mice (Figure 8G-H). 
Notably, we found that plasma bilirubin correlates poorly with cholestatic itch in 
patients and in cholestatic animals (Figure 8I). We hypothesized that the levels of 
bilirubin in the skin would correlate better with itch than serum bilirubin largely because 
bilirubin likely binds and activates the sensory neurons in the skin. Unlike with serum, 
skin bilirubin appears to be a much stronger predictor of itch severity in mice (Figure 8J). 
This is consistent with how the anatomical distribution of itch sensory neurons and may 
explain why studies aimed at identifying plasma pruritogens that correlate with itch 
severity may have missed bilirubin. Secondarily, we find that plasma bilirubin does not 
correlate well with skin bilirubin, further suggesting that plasma bilirubin may be a poor 
predictor of itch severity and may not necessarily serve as a proxy for skin bilirubin 
(Figure 8K). The amount of bilirubin in the skin is likely affected by several factors and 
equilibria, such as serum albumin. 
We assessed whether pharmacologically antagonizing MRGPRs could alleviate 
cholestatic itch. Recently, a 3-amino acid peptide, QWF, was identified as an MRGPRA1 
antagonist (Azimi et al., 2016). QWF abolished bilirubin-associated calcium signaling in 
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MRGPRA1-expressing cells with an IC50 of 2.9 M [1, 5] (Figure 12A). Mirroring its 
pharmacology in vitro, co-injecting 0.25 mg/kg QWF with bilirubin significantly 
alleviated pruritus associated with bilirubin (Figure 12B). QWF specifically antagonized 
Figure 12. QWF treatment blocks bilirubin activation of Mrgpra1 and cholestatic 
pruritus. (A) Concentration-response curve for bilirubin induced Ca2+ signal in MRGPRA1-
expressing HEK cells. 200 µM bilirubin was maintained in competition with indicated doses of 
QWF. Mean ± s.e.m. depicted. n=3 replicates in duplicate. (B-C) Scratching bouts from (B) 60 
µg (100 mL of 1 mM) bilirubin or (C) 150 µg chloroquine co-injected with either vehicle or 1 
mg/kg QWF. After injection, the number of scratching bouts in 30 min was assessed. For 
bilirubin: Vehicle n=7, QWF n=8. For chloroquine: Vehicle n=4, QWF n=7. (D) Scratching 
bouts from WT ANIT-treated animals. Either vehicle or 1 mg/kg QWF was delivered i.p. 
Vehicle n=8, QWF n=9. (E-H) Plasma (E) bilirubin, (F) AST, (G) ALT, and (H) ALP levels from 
of vehicle and QWF-dosed WT animals that have undergone ANIT liver injury. (B-H) Mean ±
s.e.m. depicted. Open circles represent independent data points. n.s., not significant; *, P < 
0.05 by two-tailed unpaired Student’s t-test.
bilirubin, as it did not attenuate chloroquine-MRGPRA3 associated itch (Figure 12C). 
Lastly, we evaluated whether the MRGPRA1 antagonist QWF could alleviate cholestatic 
pruritus. We dosed WT animals with ANIT as previously described, but intraperitoneally 
injected mice with either vehicle or 1 mg/kg QWF thirty minutes prior to behavioral 
analysis. Mice treated with QWF scratched significantly less than vehicle-treated animals 
(Figure 12D). QWF treatment did not change plasma levels of total bilirubin, AST, ALT, 
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or ALP, suggesting that QWF treatment did not alter the underlying liver pathology 
(Figure 12E-H). 
Nasobiliary drainage is the most effective treatment for cholestatic pruritus 
(Hegade et al., 2016). Based on this clinical observation, we predicted that plasma 
isolated from cholestatic animals would elicit pruritus (Figure 13A). Indeed, plasma 


















Cirrhosis 5D Itch 
Score 
(5-25)
1 28 M PSC 185 34.6 1.9 6.1 0.5 216.7 yes 5*
2 52 F
secondary biliary 
cirrhosis 80 24.5 3.4 6.3 0.7 217.5 yes 10
3 56 M
Transplant/biliary 
stricture 41 6.7 3.9 7 1.3 167.8 no 25
4 43 F PBC 68 8.5 2.5 6.2 0.8 203.4 yes 21*
5 45 F PSC 589.95 46.0 3.2 4.5 1.5 238.8 yes 21
6 47 F Alcohol 224.01 48.2 3.1 6.3 0.7 183.0 yes 13
Ctrl 
ID
Age Sex Indirect 
Bilirubin 
(µM)
1 34 F 0.91
2 58 F 0.86
3 56 M 0.70
4 30 F 0.78
5 38 F 0.77
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Figure 13. Bilirubin from mouse and human cholestatic plasma contributes to pruritus in 
a Mrgpra1-dependent manner. (A) Experimental flowchart of plasma injection assay. (B)
Scratching bouts from WT mice injected with either vehicle- or ANIT-treated plasma from WT 
and BVR KO animals. For the vehicle plasma cohort: n=7. For cholestatic ANIT-treated plasma: 
WT n=10 and BVR KO n=8. (C) Scratching bouts from either WT or A1 KO mice injected with 
control donor plasma. Ctrl 1, WT n=5, A1 KO  n=5. Ctrl 2, WT n=5, A1 KO n=5. Ctrl 3, WT n=5, 
A1 KO n=4. Ctrl 4, WT n=4, A1 KO n=5. Ctrl 5, WT n=4, A1 KO n=4. Ctrl 6, WT n=4, A1 KO 
n=4. (D) Scratching bouts from either WT or A1 KO mice injected with either cholestatic patient 
plasma. Patient 1, WT n=7, A1 KO n=9. Patient 2, WT n=8, A1 KO n=5. Patient 3, WT n=7, A1 
KO n=8. Patient 4, WT n=6, A1 KO  n=8. Patient 5, WT n=5, A1 KO n=6. Patient 6, WT n=7, A1 
KO n=5. (E) Scratching bouts from either WT or A1 KO mice injected with plasma collected from 
all tested control donor samples and all tested cholestatic patient samples. For Control: WT 
n=27, A1 KO n=27. For cholestatic patient: WT n= 41, A1 KO n=41. (F-G) Biochemical 
characteristics of patient and control plasma. (F) Age, sex, and bilirubin levels of control plasma 
collected. All control plasma donors did not suffer from any chronic itch condition. (G) 5D itch 
questionnaire was administered at time of plasma collection. Asterisk denotes patients taking 
anti-pruritic medication at time of plasma collection and questionnaire administration. Patient 1 
was taking sertraline (100mg QD) and Patient 4 was taking Gabapentin (800 mg TID). A score 
of 25 represents the maximum level of itchiness. (H) Scratching bouts from mice injected with 
either untreated (NT) control human plasma, FeCl3-treated control human plasma, NT 
cholestatic patient 1 and 4 plasma (same data from Patient WT data in (D), or FeCl3-treated 
patient plasma. For control plasma, NT n=6 and FeCl3 n=5. For Patient 1 plasma, NT n=7 and 
FeCl3 n=7. For Patient 4 plasma, NT n=7 and FeCl3 n=6. (I) Scratching bouts from mice injected 
with either normal rabbit IgG –treated patient plasma or anti-bilirubin IgG – treated patient 
plasma. For Patient 1, Normal IgG n=5, Anti-bilirubin n=7.  For Patient 4, Normal IgG n=5, Anti-
bilirubin n=6. (B-I) Mean ± s.e.m. depicted. Open circles represent independent data points. n.s., 
not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired two-tailed Student’s t-test.
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from WT animals with cholestasis elicited itch when injected into naïve WT animals 
(Figure 13B). Cholestatic plasma isolated from BVR KO mice, which lacks bilirubin 
(Figure 11B-D), elicited significantly fewer scratches than WT cholestatic plasma 
(Figure 13B). The levels of ALP, AST, and ALT were indistinguishable between WT 
and BVR KO cholestatic plasma (Figure 9A-D), presumably because ANIT induced 
similar hepatotoxicity in WT and BVR KO mice. Instead, BVR KO plasma likely results 
in less pruritus because it lacks bilirubin. 
We also isolated plasma from six patients suffering from various conditions that 
result in hyperbilirubinemia and six age- and sex-matched control patients (Figure 13C-
G). All six cholestatic patients’ plasma evoked itch in WT animals (Figure 13D). When 
injected into A1 KO animals, each patient’s plasma elicited less itch (Figure 13D). 
Compared to plasma from itchy patients, plasma from healthy donors with low levels of 
bilirubin elicited less itch in WT animals (Figure 13C). Plasma from healthy donors 
injected into A1 KO animals elicited similar scratching behavior (Figure 13C). To assess 
whether removing bilirubin from cholestatic plasma may be therapeutic, we depleted 
bilirubin both by selective oxidation with FeCl3 or an anti-bilirubin antibody before 
evaluating its pruritic capacity. We verified depletion of bilirubin by HPLC (Figure 14A-
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B). Injecting WT mice with plasma (cholestatic patients 1 and 4) treated with FeCl3 or an 
Figure 14. FeCl3 and anti-bilirubin 
antibody depletion of plasma bilirubin. 
(A) Representative HPLC chromatogram of 
100 μM biliverdin + 100 μM bilirubin 
standards and treated plasma samples. 
Absorbance was measured at 405 nm. (B)
Quantification of plasma bilirubin in 
untreated, FeCl3, normal rabbit IgG, and 
bilirubin antibody-treated samples. Points 
represent technical replicates. Mean ± s.e.m. 
depicted **, P < 0.01; n.s., not significant by 
two-way ANOVA followed by post-hoc Tukey 
test.
 
anti-bilirubin antibody evoked less pruritus compared to untreated or control IgG-treated 
patient plasma (Figure 13H-I). 
    
 
 43  
3.2 MRGPRX4 is a G-protein coupled receptor activated by bile acids that may 
contribute to cholestatic pruritus (text adapted from Meixiong et al., PNAS 2019)  
Once we identified murine receptor Mrgpra1 and human receptor MRGPRX4 as 
receptors for bilirubin that may mediate a component of cholestatic itch, I screened 
additional bile constituents against a panel of both mouse and human MRGPRs. From 
this screen, bile acids were identified as potential Mrgpr ligands. Primary bile acids are 
formed in liver hepatocytes via cytochrome P450 (CYP) metabolization of cholesterol 
(Figure 15A). Primary bile acids are further metabolized to form additional bile species 
before being conjugated to either glycine or taurine for more efficient biliary secretion. In 
the intestine, bacteria metabolize bile acids to form secondary bile acids, which can 
return to the bloodstream and liver through enterohepatic circulation (Figure 15A).  
As measured by intracellular Ca2+ changes, numerous bile acids, both primary and 
secondary, activated MRGPRX4. (Figure 15B-C). We tested bile acid activity against 12 
closely related mouse Mrgprs (Figure 16A) as well as sequence-similar human receptors, 
MRGPRX1-3. No mouse receptors, including the previously identified mouse ortholog  
Mrgpra1 or sequence-similar human receptors, were activated by bile acids (Figure 16B-
E). Based on this result, we concluded that bile acids specifically activated MRGPRX4 
among the Mrgpr family members. 
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Figure 15. Bile acids activate MRGPRX4, a human sensory neuron expressed GPCR. (A) 
The molecular stereostructures of primary and secondary bile acids and their metabolic 
precursor, cholesterol. Major structural differences are highlighted in red. R1 denotes the 
potential presence of an α hydroxyl substituent in some bile acid derivatives. R2 denotes 
additional substituents that vary among bile acids. (B-H) Ca2+ imaging of HEK293 cells stably 
expressing MRGPRX4. (B) Representative Fura-2 fluorescence heat map images of HEK cells 
showing changes in intracellular [Ca2+] induced by deoxycholic acid (10 µM). Scale bar, 20 µm. 
(C, F) Concentration–Ca2+ response curves of bile acids against MRGPRX4. Data are a 
representative experiment of 3 independent replicates performed in triplicate, depicted as 
mean ± s.e.m. (C) Concentration–Ca2+ response curves of unconjugated bile acids: 
deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), cholic 
acid (CA), and oleic acid (OA). (F) Concentration–Ca2+ response curves of tauro-conjugated 
bile acids: deoxycholic acid (TDCA), chenodeoxycholic acid (TCDCA), and cholic acid (TCA). 
(D-E, G-H) Ca2+ imaging traces. 10 µM deoxycholic acid (DCA) was added where indicated by 
black bars. Mean ± 95% confidence interval (CI) depicted. n= 15. In (E, G, H), cells were pre-
incubated with either 10 µM SERCA inhibitor thapsigargin (E), 10 µM of the Gαq inhibitor 
YM254890 (G), or 10 µM PLC inhibitor U73122 (H) for 30 min prior to imaging. 
 
 Ca2+ imaging of MRGPRX4-expressing HEK293 cells displayed robust Ca2+ flux 
in response to 10 M deoxycholic acid (DCA) (Figure 15B, D). Thapsigargin, a non-
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competitive inhibitor of the sarco-endoplasmic reticulum Ca2+ ATPase, completely 
inhibited bile acid-associated Ca2+ influx (Figure 15E), indicating that MRGPRX4- 
induced Ca2+ signal was dependent on intracellular Ca2+ stores. Previous studies have 
identified MRGPRX4 as being Gq-linked (Lansu et al., 2017; Meixiong et al., 2019). In 
line with this, DCA-associated Ca2+ flux appears to be similarly Gq-linked, since both 
the Gq inhibitor, YM254890, and the PLC inhibitor, U73122, inhibited Ca
2+ signal 
(Figure 15G-H). 
Figure 16. DCA does not activate the murine ortholog Mrgpra1 or related human Mrgprs. (A) 
Graphical depiction of DCA-screened murine Mrpgrs. (B-E) Ca2+ imaging of HEK293 cells stably 
expressing (B) MRGPRA1, (C) MRGPRX1, (D) MRGPRX2, or (E) MRGPRX3. Mean ± 95% CI 
depicted. n=10. 10 µM DCA was added where indicated by black bars., When applicable, a positive 
control was added at the end of imaging trial, (B) 30µM FMRF, (C) 3 µM BAM8-22, or (D) 10µM 
PAMP9-20. (F) Table of EC50s with 95% confidence intervals(CI) of unconjugated bile acids against 
MRGPRX4. (G) Table of EC50s with 95% CI of tauro-conjugated bile acids against MRGPRX4. 
 
 Of the bile acids tested, DCA and ursodeoxycholic acid (UDCA) displayed the 
highest potency in terms of MRGPRX4-associated Ca2+ signal (Figure 15C, Figure 16F). 
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Both DCA and UDCA had EC50s of approximately 5 M, similar to their activity towards 
previously published receptors like TGR5 (Kawamata et al., 2003). Unlike TGR5 
however, MRGPRX4 displayed a larger range of potency for various bile acids. For 
example, cholic acid (CA), displayed much lower potency against MRGPRX4 (EC50 ~ 
430 M), well outside physiologic range. In contrast, the EC50 of CA towards TGR5 is 
approximately 10 M (Kawamata et al., 2003).  
 Primary bile acids can be conjugated to either glycine or taurine to form water-
soluble bile salts. We tested three tauro-conjugated bile acids, tauro-DCA (TDCA), tauro-
CDCA (TCDCA), and tauro-cholic acid (TCA) against MRGPRX4. All conjugated bile 
acids were capable of activating MRGPRX4 at concentrations similar to the respective 
unconjugated bile acid (Figure 15F, Figure 16G).  
 MRGPRX4 is primarily expressed in sensory neurons of the dorsal root ganglia 
(DRG). In order to test whether bile acids interact with MRGPRX4 in neurons, we 
generated humanized mice expressing MRGPRX4. We crossed Tg(Mrgpra3-GFP-Cre) 
(A3-Cre) animals with newly generated ROSA26loxSTOPloxl-MRGPRX4 (lsl-MRGPRX4) 
animals (Figure 17A). A3-Cre animals express Cre recombinase under control of the 
Mrgpra3 promoter, which labels approximately 5% of the dorsal root ganglia sensory 
neurons that specifically encode for itch (Han et al., 2013). In lsl-MRGPRX4 animals, 
expression of MRGPRX4 is under Cre-loxp control. Progeny that inherit both A3-Cre 
and lsl-MRGPRX4 (+X4) would be expected to express MRGPRX4 in mouse Mrgpra3-
containing itch neurons (Figure 17A). Cre-null but transgene-positive mice (Cre-, lsl-
MRGPRX4) were studied as comparative controls. 
    
 





























































































































































































Figure 17. +X4 humanized mouse sensory neurons are more readily activated by bile 
acids. (A) Diagram showing mating strategy to generate humanized (+X4) mice. Mrgpra3-cre 
expression is restricted to mouse dorsal root ganglia (DRG). Approximately 5% of DRG would 
be expected to express receptor. qPCR (B) and (C) RT-PCR of RNA collected from both control 
(A3-Cre negative) and +X4 (A3-Cre positive) mice expressing Rosa26lsl-MRGPRX4. (B) Mean ±
95% CI depicted. n=3 representative samples. ***, P < 0.001, student’s t test. (C) Arrow 
indicates the expected band based on primer design. 4 independent samples collected from 
different mice depicted. (D, H) Ca2+ imaging traces of Ctrl and +X4 DRG neurons.  Mean ±95% 
CI depicted. n=10 neurons. After a 10 s baseline, either 10 µM DCA (D) or 100 µM UDCA (H) 
applied where indicated by black bars. After 1 min, 1 mM chloroquine was added. (E, I) Percent 
activation of Ctrl and +X4 DRG neurons from either 10 µM DCA (E) or 100 µM UDCA (I). (F, J) 
Percent overlap of CQ activated Ctrl and +X4 DRG neurons (~5% of total) activated by both 
DCA and CQ (F) and both UDCA and CQ (J). (E-F, I-J) *, P < 0.05; **, P < 0.01; Chi-squared 
test. A neuron was considered to be activated if ∆F > 0.2 for at a least 30 s. (G, K) Venn 
diagrams of DCA (G), UDCA (K), and CQ activated neurons as a percent of total DRG neurons.
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 +X4 animals expressing A3-Cre and lsl-MRGPRX4 have high levels of 
MRGPRX4 mRNA in sensory neurons as assayed by both qPCR and RT-PCR (Figure 
17B-C). Based on previously determined potencies, we selected DCA and UDCA for 
further experimentation. As assayed by Ca2+ imaging, DCA activated a subpopulation of 
small diameter (approximately 20 m) +X4 DRG neurons (Figure 17D; Figure 18A-B). 
Figure 18. DCA activates small-diameter Ctrl and +X4 sensory neurons. (A-B) 
Histograms of bilirubin-activated neuronal soma diameter. (A) +X4 Mean = 18.8µm. 
n= 47. (B) Ctrl Mean = 20.1µm. n= 35. 
At the tested concentration, TGR5 receptor present in both control (Ctrl) and +X4 
neurons would be activated. Indeed, DCA activated 3.4% of control neurons, likely due 
to activation of TGR5 (Figure 17E). Approximately 25% of control neurons activated by 
DCA were also activated by chloroquine (CQ), a ligand for Mrgpra3 (Figure 17F-G). 
Based on the genetic strategy employed for +X4 generation, we hypothesized that DCA 
would activate a higher percentage of Mrgpra3, CQ-sensitive, sensory neurons in +X4 
animals. DCA activated 6.4% of +X4 sensory neurons (Figure 17E). In addition, DCA 
activated significantly more CQ-sensitive, Mrgpra3-expressing, neurons in +X4 DRG 
(Figure 17F-G). Based on this data, we concluded that +X4 humanized sensory neurons 
expressed functional MRGPRX4 receptor that could be activated by DCA.  
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 TGR5 has been previously identified as being expressed in Mrgpra3-positive itch 
neurons (Alemi et al., 2013). To better disambiguate MRGPRX4 and TGR5 activity, we 
selected UDCA as a ligand for additional experimentation. All bile acids tested against 
MRGPRX4 are reported to activate TGR5 (Sato et al., 2008). However, UDCA, the 
second most potent activator of MRGPRX4, is a significantly less potent TGR5 agonist 
(Kawamata et al., 2003). Based on these data, we predicted that lower concentrations of 
UDCA would activate more +X4 neurons than control neurons. Indeed, UDCA activated 
a similar percentage of +X4 DRG neurons compared to DCA but activated a significantly 
smaller percentage of control neurons (Figure 17H-I). Additionally, UDCA activated 
only 10% of CQ-sensitive control neurons while activating 54% of +X4 neurons (Figure 
17J-K). 
 To test the in vivo relevance of bile acid agonism of MRGPRX4, we injected bile 
acids into control and +X4 animals and assessed acute itch. As before, the genetic 
strategy of MRGPRX4 humanization results in +X4 animals expressing MRGPRX4 
receptor in Mrgpra3+ itch neurons. Therefore, we hypothesized that a true, in vivo ligand-
MRGPRX4 interaction would activate Mrgpra3+ neurons and produce itch behavior. 
Compared to control, +X4 animals scratched significantly more in response to injection 
of pathophysiologic concentrations of DCA, UDCA, CDCA, and TDCA at the nape 
(Figure 19A-D). This increase was specific to bile acids, as histamine and chloroquine, 
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Figure 19. +X4 humanized mice scratch more to unconjugated and conjugated bile 
acids. (A) Scratching bouts associated with injection of DCA. 50 µL of 1 mM DCA was injected 
into the nape of Ctrl and +X4 mice. Ctrl n=13; +X4 n=6. (B) Scratching bouts associated with 
injection of T-DCA. 50µL of 1mM T-DCA was injected into the nape of Ctrl and +X4 mice. Ctrl 
n=9; +X4 n=5. (C) Scratching bouts associated with injection of UDCA. 50 µL of 2 mM UDCA 
was injected into the nape of Ctrl and +X4 mice. Ctrl n=6; +X4 n=6. (D) Scratching bouts 
associated with injection of CDCA. 50 µL of 2 mM CDCA was injected into the nape of Ctrl and 
+X4 mice. Ctrl n=6; +X4 n=6. (E) Scratching bouts associated with injection of human plasma 
from either normal or cholestatic patients (Chol) into Ctrl and +X4 mice. 50 µL of plasma was 
injected into the nape of mice. For normal plasma: Ctrl n= 5; +X4 n=7. For Chol plasma: Ctrl 
n= 5; +X4 n=5. (A-D) Mean ± s.e.m. depicted. Each open circle represents an individual 
mouse. (A-D) *, P < 0.05; **, P < 0.01; ***, P < 0.001; two-tailed unpaired Student’s t-test. 
two canonical pruritogens, stimulated similar levels of itch in control and +X4 animals 
(Figure 20A-B). Additionally, injection of cholestatic patient plasma, containing bile 
acids and numerous other pruritogens (Figure 19C), elicited greater itch in +X4 animals 
compared to control animals (Figure 19D). This difference between Ctrl and +X4 
animals was not observed upon injection of control plasma (Figure 19D). Compared to 
normal plasma, patient plasma elicited greater itch in control animals (Figure 19D). This 
could result from numerous pruritogens acting at established itch receptors in mice, such 
as bilirubin at Mrgpra1 or bile acids at TGR5.   
Having established that unconjugated and conjugated bile acids elicited greater 
acute itch in +X4 animals, we sought to determine whether this observation remained true 
in a mouse model of cholestatic itch. To induce cholestasis, we administered -napthyl 
isothiocyanate (ANIT) to mice. ANIT is a well-established model that elicits intrahepatic 
cholestasis in mice (Meixiong et al., 2019; Tanaka et al., 2009). We treated control and 
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Figure 20. +X4 humanized mice 
scratch normally in response to 
non-bile acid pruritogens. (A) 
Scratching bouts associated with 
injection of histamine. 50µL of 9mM 
histamine was injected into the nape 
of Ctrl and +X4 mice. Ctrl n=6; +X4 
n=6. (B) Scratching bouts associated 
with injection of Chloroquine (CQ). 
50µL of 10 mM CQ was injected into 
the nape of Ctrl and +X4 mice. Ctrl 
n=6; +X4 n=5. (C) Biochemical 
characteristics of patient plasma 
injected.
+X4 animals with 25 mg/kg ANIT daily for five days while assessing spontaneous itch 
and weight 24 hours after each treatment (Figure 21A). Over the course of the 
experiment, cholestatic itch in +X4 animals was significantly different from control 
ANIT
25mg/kg daily
















































































































Figure 21. +X4 humanized mice display increased cholestatic itch concordant with 
serum bile acid elevation. (A) Experimental flowchart of cholestatic model. ANIT was given 
daily per os for 5 days. 24 hours subsequent to every treatment, spontaneous itch was 
assessed for 1 hour. (B) Spontaneous scratching bouts from ANIT-treated animals. itch was 
assessed for 1 hour. Scratching bouts from Ctrl and +X4 were significantly different. P<0.05 by 
ANOVA. For Day 0: Ctrl n= 5, +X4 n=7. For Day 1: Ctrl n= 14, +X4 n= 11. For Day 2: Ctrl n= 
13, +X4 n= 9. For Day 3: Ctrl n= 11, +X4 n= 9, For Day 4: Ctrl n= 10, +X4 n= 9. For Day 5: Ctrl 
n= 7, +X4 n= 9. (C) Percent weight change from baseline of Ctrl and +X4 mice during ANIT 
treatment. For Day 1: Ctrl n= 5, +X4 n= 7. For all other days: Ctrl n= 4, +X4 n= 6. (D) Plasma 
bile acid levels from Ctrl and +X4 mice at indicated days of ANIT treatment. For Day 0: Ctrl n= 
4, +X4 n=4. For Day 1: Ctrl n= 6, +X4 n= 9. For Day 5: Ctrl n= 6, +X4 n= 7. (E) Total plasma 
bilirubin levels at indicated days of treatment. For Day 1: Ctrl n= 3, +X4 n= 3. For Day 5: Ctrl 
n= 5, +X4 n= 9. (B-E) Mean ± SEM depicted. Circles represent individual mice. n.s.= not 
significant; *, P < 0.05; **, P < 0.01; student’s t test. 
animals (Figure 21B). The majority of this difference was observed at early timepoints. 
Specifically, +X4 animals scratched significantly more than baseline just 24 hours after a 
single dose of ANIT (Figure 21B). ANIT does not appear to directly activate MRGPRX4, 
since acute treatment of ANIT did not elicit itch in either WT or +X4 animals over the 
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first hour after administering ANIT (Figure 22A). Subsequent treatment did not 
significantly increase pruritus. In control animals, itch was not significantly elevated until 
the third day of treatment (Figure 21B). Like +X4 mice, control mice did not scratch 
more with subsequent treatments. During days 3-5 of treatment, control and +X4 itch 
were indistinguishable (Figure 21B). Control and +X4 animals displayed no differences 
in weight change from ANIT treatment. Both groups lost significant weight over the 5-
day treatment course (Figure 21C). Control and +X4 animals had similar degrees of 
cholestatic injury after either 1 or 5 days of ANIT treatment, as assessed by plasma levels 
of bile acids, total bilirubin, albumin, aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), and alanine aminotransferase (ALT) (Figure 21D-E; Figure 22B-E).  
Based on observed time course of itch behavior, we hypothesized that humanized 
+X4 mice scratched more at earlier timepoints due to a ligand of MRGPRX4, such as bile 
acids, being elevated during those periods. Indeed, at Day 1, ANIT treatment resulted in 
significant elevation of plasma bile acids, similar to levels observed on Day 5. 
Figure 22. +X4 humanized mice exhibit similar degrees of cholestasis compared to Ctrl 
mice. (A) Scratching bouts from wild-type and +X4 animals 1 hour after a single 25mg/kg dose 
of ANIT. For both WT and +X4, n=3. (B) Plasma albumin levels (g/dL) from indicated days of 
ANIT treatment. (C) Plasma aspartate aminotransferase (AST) levels (U/L) from indicated 
days of ANIT treatment.  (D) Plasma alkaline phosphatase (ALP) levels (U/L) from indicated 
days of ANIT treatment. (E) Plasma alanine aminotransferase (AST) levels (U/L) from 
indicated days of ANIT treatment. (A-E) Mean ± SEM depicted. Circles represent plasma from 
individual mice. For Day 1: Ctrl n= 3, +X4 n= 5. For Day 5: Ctrl n= 5, +X4 n= 9.  n.s.= not 
significant; *, P < 0.05; **, P < 0.01; student’s t test. 
Importantly, plasma bilirubin, albumin, and liver enzyme levels were not elevated at Day 
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1 (Figure 21E; 22B-E). This distinction suggested that the increase in itch on Days 1-2 
in +X4 animals resulted from an increase in bile acids and not bilirubin, another ligand of 
MRGPRX4. We hypothesized that +X4 cholestatic itch is similarly elevated compared to 
control at later timepoints (Days 3-5) due to signaling from intact bilirubin itch receptor 
Mrgpra1 in Ctrl animals and other potential pruritogen-receptor interactions.  
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3.3 Activation of mast cell-expressed Mas-related G-protein coupled receptors 
drives non-histaminergic itch (text adapted from Meixiong et al., Immunity 2019) 
In addition to exploring the role of sensory-neuron expressed Mrgprs in non-
histaminergic itch, I was interested in assessing the contribution of mast cell-expressed 
Mrgprs in itch. In the context of nociceptive itch (i.e., pruriception), mast cells are key 
cellular mediators via release of histamine which activates receptors present on itch-
sensory neurons of the dorsal root ganglia (DRG) (Shim and Oh, 2008). Canonically, 
mast cell activation is understood to result from antigen binding to immunoglobulin E 
(IgE) antibody and crosslinking of the high-affinity IgE receptor, Fc epsilon RI (FcRI). 
Activation of either Mrgprb2 or MRGPRX2 results in mast cell degranulation that is both 
spatially and temporally distinct from FcεRI-mediated degranulation (Gaudenzio et al., 
2016; McNeil et al., 2015). These observations provoke the hypothesis that mast cell 
Mrgpr pathways may promote itch in a unique fashion separate from classical IgE-
mediated itch.  
Despite their well-described roles in histaminergic itch, how mast cells interact 
with pruriceptive sensory nerves in vivo has not been investigated. Here we report that 
activation of mast cells via Mrgprb2 induced itch distinct from classical IgE-FcεRI 
histaminergic itch. Compared to FcεRI activation, Mrgprb2 activation resulted in 
differential release of pruritogens. Using intravital Ca2+ imaging of sensory neurons, we 
showed that Mrgprb2-stimulation of mast cells, compared to IgE-FcεRI signaling, 
activated a distinct population of itch-sensory neurons. Histamine H1 receptor (H1R) 
blockade is not effective in treating numerous chronic itch disorders associated with mast 
cell activation such as allergic contact dermatitis (ACD)  (Askenase et al., 1983; Dudeck 
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et al., 2011; Erickson et al., 2018; Gimenez-Rivera et al., 2016; Grimbaldeston et al., 
2007). In contrast, we demonstrated that Mrgprb2 was critical for itch in the setting of 
ACD and thus a possible target for therapeutic intervention. 
Mrgprb2 (murine) and MRGPRX2 (human) are expressed in mast cells and not in 
other immune or neuronal cells (Flegel et al., 2015; McNeil et al., 2015; Motakis et al., 
2014). We confirmed that Mrgprb2 expression was specific to mast cells and not sensory 
neurons by crossing Mrgprb2-Cre mice expressing Cre recombinase under control of the 
Mrgprb2 promoter with a tdTomato (tdT) reporter mouse line (Mrgprb2-Cre;tdT). 
Mrgprb2-Cre;tdT mice had no detectable tdT fluorescence in either DRG or spinal cord 


































Figure 23. Mrgprb2 is not expressed in dorsal root ganglia sensory neurons and the spinal cord. 
Dorsal root ganglia (DRG) (A, Aʹ) and spinal cord (B, Bʹ) sections taken from Mrgprb2-Cre; tdTomato
animals, mice expressing both Mrgprb2-Cre and lox-stop-lox tdTomato (tdT) fluorescent reporter. 
Isolectin B4 conjugated to Alexa Fluor 488 depicted in green in DRG (A) and the spinal cord (B). tdT
fluorescent reporter is undetectable in both DRG (Aʹ) and the spinal cord (Bʹ). (C) Skin section taken from 
MRgprb2-Cre; tdT mouse. Red depicts positive tdT staining of mast cells. (D) Stringent RT-PCR for 
Mrgprb2 from cDNA collected from two dorsal root ganglia, spinal cord, and mast cell preps. Experiment 
was repeated at least two times. The arrow indicates the expected band size for Mrgprb2.
using RT-PCR (Figure 23D). We employed pro-adrenomedullin peptide 9-20 (PAMP9-
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20) and compound 48/80, previously identified ligands of Mrgprb2 and MRGPRX2 
(McNeil et al., 2015), to test whether activation of mast cells via Mrgprs was sufficient to 
induce itch in vivo. PAMP9-20 is a potent hypotensive peptide that is produced by a 
variety of cell types including cells of the adrenal medulla and keratinocytes (Kapas et al., 
2001; Kuwasako et al., 1997) and compound 48/80 is a canonical basic secretagogue 
activator of mast cells (Paton, 1951). Subcutaneous injection of either PAMP9-20 or 
compound 48/80 elicited itch in wild-type (WT) mice (Figure 24A, 25A) that was 
reduced in Mrgprb2-deficient (Mrgprb2-/-) mice (Figure 24A, 25A). Neither substance 
elicited pain in the cheek model of behavior (i.e., wiping), indicating the specificity of 
acute Mrgprb2 activation for itch (Figure 24B, 25B-C). To test whether pruritus resulted 
from mast cell activation, we injected PAMP9-20 into both cromolyn-treated and cKitW-sh 
(SASH) mice. Cromolyn is a mast cell stabilizer that inhibits granule release while SASH 
mice are c-Kit receptor-deficient animals that lack mast cells. Both cromolyn-treated 
animals and SASH mice displayed reduced PAMP9-20 itch compared to control animals 
(Figure 24C-D). Mrgprb2-/- animals had intact mast cell itch responses to non-Mrgpr 
stimuli such as acute injection of anti-IgE, an antibody against mouse IgE, and repeated 
ovalbumin (OVA) exposure (Figure 24E-F). Anti-IgE directly crosslinks IgE and 
activates FcεRIα, while OVA sensitization results in a variety of OVA-specific immune 
responses including the generation of OVA-specific IgE (Reddy et al., 2012). Although 
the cellular expression of FcεRIα differs between mice and humans (de Andres et al., 
1997), in mice, anti-IgE would be expected to specifically activate skin-resident mast 
cells (Figure 25D-E).  
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Figure 24. Mrgprb2 agonist PAMP9-20 elicited non-histaminergic itch and differential 
pruritogen release compared to FcεRI activation. (A-H) Scratching bouts from injection of 
pruritogen at either the nape or the cheek. Mean plus s.e.m. depicted. Each open circle 
represents an independent mouse data point. (A-B) PAMP9-20 injection into either nape 
(50µL) (A) or cheek (10µL) (B) of WT and Mrgprb2-/- (B2 -/-) animals. (A) 8 µg: WT n= 6, B2-/-
n= 7; 24 µg: WT n= 13, B2-/- n= 12; 40 µg: WT n=5, B2-/- n=5. (B) 4.8 µg: WT n= 4, B2-/- n= 
4; 8 µg: WT n=5, B2-/- n= 4. (C) Injection of 24 µg PAMP9-20 (50µL of 300µM) at the nape in 
the presence of either vehicle or cromolyn. Veh n=9, Cromolyn n= 8. (D) Injection of 24 µg 
PAMP9-20 (50µL of 300µM) into the nape of WT and SASH (cKitW-sh) mice. For both, n = 8. 
(E) 1µg anti-IgE injection into WT and B2 -/- mice. WT n= 7, B2 -/- n= 6. (F) 50 µg ovalbumin 
injection into sensitized WT and B2 -/- animals. WT n= 6, B2 -/- n= 9. (G) 1µg anti-IgE injection 
at the cheek with the indicated antagonist. Vehicle, n= 13; H1Blocker, n= 9; H4Blocker, n= 14; 
Ritanserin, n= 10; Mianserin, n=6; Cyproheptadine, n=8; Ondansetron, n= 5. (H) 24 µg 
PAMP9-20 injection at the nape with the indicated antagonist. Vehicle, n= 15; H1Blocker, n= 
11; H4Blocker, n= 16; Ritanserin, n= 14; Mianserin, n=6; Cyproheptadine, n=8; Ondansetron, 
n= 5. In vitro release of histamine (I), serotonin (J), and tryptase beta 2 (K) from mouse 
peritoneal mast cells upon stimulation by various concentrations of either PAMP9-20 or anti-
IgE. For (J) PAMP9-20: 2.5 n=8; 25 n=5; 125 n=7. For Anti-IgE: 2.5 n= 5; 8 n= 7; 25 n= 8. 
Open circles depict independent biological replicates from peritoneal mast cells isolated from > 
4 animals. For (I-K), mean plus s.e.m. depicted. Open circles depict independent biological 
replicates from peritoneal mast cells isolated from > 2 animals. All concentrations n=3. (A-K) *, 
P < 0.05; ***, P < 0.001; n.s. = not significant by two-tailed unpaired Student’s t-test. 
 
Both histamine (H1 and H4) and serotonin (5-HT2 and 5-HT7) receptor antagonism 
have been reported to be effective in controlling various forms of mast cell-associated 
itch (Dunford et al., 2007; Katagiri et al., 2006; Morita et al., 2015; Shim and Oh, 2008; 
Yamaguchi et al., 1999). Indeed, cetirizine (H1R antagonist), JNJ7777120 (H4R 
antagonist), and serotonin receptor antagonists ritanserin, mianserin, and cyproheptadine 
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substantially reduced anti-IgE-associated itch (Figure 24G).  In contrast, PAMP9-20-





















































































































































































D E F G
40 ng 80 ng200 ng 2 µg
Figure 25. Mrgprb2 agonists elicit itch and not pain. (A-C) Mean plus s.e.m. depicted. 
Each open circle represents an individual mouse. (A) Scratching bouts from injection (50µL) of 
compound 48/80 into the nape of the neck of WT and Mrgprb2-/- mice. For 200 ng: WT n= 5, 
B2 -/- n= 5; 2 µg: WT n=5, B2 -/- n= 5. (B) Scratching bouts associated with injection (10µl) of 
compound 48/80 into cheek of WT or B2 -/- animals. For 40 ng: WT n= 7, B2 -/- n= 7; 80 ng: 
WT n=6, B2-/- n= 5. (C) Wiping associated with injection (10µl) of the indicated substance into 
the cheek of WT animals. 300µM PAMP9-20, 10µg/mL compound 48/80, and 100µg/mL Anti-
IgE were injected. Veh n= 7, PAMP9-20 n=8, Compound 48/80 n= 7, anti-IgE n=5. (D) 
Representative FACS plot of Live CD45+ Lin- CD11b- cells (basophils) from naïve cheek skin. 
(E) Quantification of the frequency of c-Kit+ Mast cells and c-Kit- Basophils (average ± SD) as 
a percentage of Lin- cells of n = 2 mice. (F) β-hexosaminidase release of mouse peritoneal 
mast cells, displayed as a percentage of total β-hexosaminidase. For all conditions, n=3. Open 
circles depict independent replicates. (G) Percent activation as detected by Ca2+ imaging of 
mouse peritoneal mast cells. ***, P < 0.001 by chi-square test. (A-G) Mean plus s.e.m. 
depicted. Each open circle represents an individual mouse. *, P < 0.05; **, P < 0.01, n.s. = not 
significant by two-tailed unpaired Student’s t-test. 
note, the concentrations of ritanserin, mianserin, and cyproheptadine utilized (1mg/kg) 
would inhibit not only serotonergic but also histaminergic receptors. Ondansetron, a 5-
HT3 antagonist, affected neither anti-IgE nor PAMP9-20 itch (Figure 24G-H). These 
data suggest that Mrgprb2 itch was not mediated by mast cell release of histamine and 
serotonin, indicating that Mrgprb2 activation may confer functions on skin-resident mast 
cells different from classical IgE-mediated activation. We stimulated murine peritoneal 
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mast cells with PAMP9-20 and anti-IgE. At concentrations where mast cells were 
similarly activated as determined by β-hexosaminidase release assay and Ca2+ imaging 
(Figure 25F-G), we detected differential release of well-known pruritogens. Compared 
to Anti-IgE, PAMP9-20 resulted in lower release of the monoamines, histamine and 
serotonin, and greater release of tryptase beta 2 (Figure 24I-K).  
In both rodents and humans, mast cells maintain a close anatomical relationship 
with sensory nerve fibers (Harvima et al., 2010). Such proximity supports a model 
whereby peptidergic sensory neurons can activate mast cells, and mast cells, in turn, can 
excite neurons via degranulation and release of effector molecules (Kleij and Bienenstock, 
2005; van Diest et al., 2012). To explore how Mrgprb2 activation of mast cells might 
stimulate sensory nerves, we performed intravital Ca2+ imaging in Pirt-GCaMP6s mice 
after peripheral injection of Mrgprb2 agonists. Pirt-GCaMP6s mice express GCaMP6s, a 
genetically encoded fluorescent Ca2+  indicator, in > 95% of sensory neurons (Kim et al., 
2014) (Figure 26A-Aʹ). Following injection of either PAMP9-20 (300M) or compound 
48/80 (10ng/L) into the footpad of the ipsilateral hindpaw (part of the L4 dermatome), 
we observed robust activation of a subset of small-diameter sensory neurons in L4 DRG 
(Figure 26A-C, 27A). PAMP9-20 and compound 48/80 activated a similar number of 
sensory neurons per trial, and both agonists activated significantly fewer neurons in 
Mrgprb2-/- mice (Figure 26B). In contrast, anti-IgE and direct activators of neurons, 
chloroquine (CQ), 5-HT, and -alanine, excited an equivalent number of sensory neurons 
in both control and Mrgprb2-/- animals (Figure 26B, D and 27B-C).  
In vitro comparisons of Mrgprb2 agonism with IgE receptor activation have 
demonstrated that Mrgprb2 agonism triggers more rapid degranulation of smaller 
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Figure 26. Differential mast cell agonism exhibited varied sensory neuron activation 
profiles. Graphical depiction (A) and experimental flowchart (Aʹ) of in vivo Ca2+ imaging of 
Pirt-Cre-GCaMP6s sensory neurons. White arrowheads indicate activated neurons. (B) Total 
number of activated neurons for the labeled compound. Mean plus s.e.m. depicted. Open 
circles represent imaging trials from independent mice. PAMP9-20: WT n= 12, B2 -/- n=5; 
compound 48/80: WT n= 5, B2 -/- n=5; Anti-IgE: WT n=3, B2 -/- n=4. (C-D) Averaged Ca2+ 
imaging traces ± 95% confidence intervals (CI) and heatmaps (Cʹ-Dʹ) of individual neurons 
activated by 300µM PAMP9-20, n= 72 and 100µg/mL anti-IgE, n = 72. (E-G) Box (25th and 75th
percentiles) and whisker (max and min) plots. (E) Time to first detected activation within trial 
period for neurons activated by the indicated test compounds. PAMP9-20 n= 95; CQ n=79; 
Anti-IgE n= 79. (F) Number of Ca2+ signal peaks (>20% increase over baseline) within imaging 
trial period. PAMP9-20 n= 74; Anti-IgE n= 85. (G) Positive peak area (Amplitude over baseline 
*Duration) within the imaging trial period. PAMP9-20 n= 74; Anti-IgE n= 85. (A-G) **, P < 0.01; 
***, P < 0.001; n.s. = not significant; two-tailed unpaired Student’s t-test. 
granules (Gaudenzio et al., 2016). Intravital Ca2+ imaging of mast cell-activated sensory 
neurons was consistent with this model. In comparison to anti-IgE-associated neurons, 
Ca2+ imaging traces of PAMP9-20-activated neurons displayed earlier excitation, 
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increased numbers of Ca2+ signal peaks, and reduced total peak area 
(Amplitude*Duration) (Figure 26E-G) (See S.T.A.R. Methods for details). Both 
PAMP9-20 and anti-IgE-associated neuronal excitation was detected later than that 
associated with chloroquine (CQ), a direct activator of neuronal Mrgpra3 (Liu et al., 2009) 
(Figure 26E, 27D-E). 



























































































Figure 27. Diameters and total numbers of identified activated neurons associated with 
mast cell agonists and neuronal activators. (A) Histogram of diameters of neurons 
activated in vivo by 300µM PAMP9-20. (B) Histogram of diameters of neurons activated in vivo 
by 100µg/mL Anti-IgE. (C) The total number of activated neurons identified within each 
imaging trial period from the labeled test compound. For CQ: WT n= 6, B2 -/- n=3; β-alanine: 
WT n= 5, B2 -/- n=3; 5-HT: WT n=3, B2 -/- n=3; capsaicin (cap): WT n=3, B2 -/- n=3; 
histamine: WT n=5, B2 -/- n=3.  Mean plus s.e.m. depicted. Open circles represent individual, 
imaged mouse DRGs. Averaged Ca2+ imaging traces (D) and heatmaps (E) of individual 
neurons (included in the average) activated by 10mM chloroquine, n= 69. Black dotted lines 
indicate the start of the test compound imaging period. The solid black line depicts the 
averaged change in fluorescence of representative, activated sensory neurons, whose 
individual fluorescent changes are illustrated in the heatmap. The red dotted lines (D) are 95% 
confidence intervals. 
 
Having established that differential activation of mast cells (IgE vs. Mrgprb2) 
exhibited global differences in neuronal activation signatures, we were interested in 
examining the specific identity of activated sensory neurons. Based on divergent itch 
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behavior (Figure 24), we hypothesized that differential activation of mast cells would 
excite separate classes of itch neurons in vivo. Single cell RNA-sequencing of mouse 
sensory neurons has determined three classes of itch neurons typified by expression of 
three G-protein coupled receptors: Mrgprd (NP1), Mrgpra3 (NP2), or 5ht1f (NP3) 
(Usoskin et al., 2015) (Figure 28A). In order to identify itch neuron subtypes activated 
by mast cell agonism, we employed specific agonists for these receptors, -alanine 
(Mrgprd), CQ (Mrgpra3), and 5-HT (5ht1f), to functionally identify neurons (Figure 
28A-Aʹ). Receptor expression is not strictly exclusive to each class of itch neuron. For 
example, a significant percentage (22%) of Mrgpra3-positive NP2 neurons express 
Mrgprd and thus would be expected to be activated by both -alanine and CQ (Usoskin et 
al., 2015). In the same imaging trial, repeat injections of the same activator should 
theoretically exhibit 100% overlap in excited neurons. However, in our trials, technical 
variability limited sensitivity. Of PAMP9-20-activated neurons, approximately 66% 
(50/76) were activated by a repeat injection of PAMP9-20. Subsequent percent overlap 
data was thus normalized to this figure. Of all tested compounds, the two Mrgprb2 
agonists, compound 48/80 and PAMP9-20, most consistently overlapped (Figure 28B). 
Mrgprb2 agonist-activated neurons exhibited broad overlap with neurons responsive to -
alanine (NP1)-, CQ (NP2)-, and 5-HT (NP3) and significantly less overlap with neurons 
sensitive to histamine and capsaicin (Figure 28C-G). In contrast, anti-IgE-associated 
neurons overlapped significantly less with neuronal classes identified by -alanine, CQ, 
and 5-HT and more with neurons responsive to histamine and capsaicin (Figure 28C-G). 
Further, both cetirizine (H1R antagonist) and JNJ7777120 (H4R antagonist) preferentially 
decreased the number of neurons detected with anti-IgE compared to PAMP9-20-elicited 
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neurons (Figure 28H). 
Figure 28. Mrgprb2 agonism excited multiple itch sensory neuron subtypes in an 
activation pattern distinct from FcεRI. (A) Graphical depiction of itch neuron subtypes. (Aʹ)
Experimental flowchart for in vivo Ca2+ imaging of mast cell agonists plus neuronal activators. 
(B) Percent overlap of activated sensory neurons from a peripheral injection of 300µM 
PAMP9-20 and either a repeat injection of 300µM PAMP9-20 n= 4 or 10µg/mL Compound 
48/80 n=3. Percent for this and subsequent data normalized to repeated PAMP 9-20 injection. 
(C) Normalized percent overlap between 300µM PAMP9-20 and either 10mM chloroquine 
(CQ) n= 5, 1mM 5-HT n=6, or 10mM β-alanine n= 5 and between Anti-IgEand either CQ n= 3, 
5-HT n=4, or β-alanine n= 4. (D) Normalized percent overlap between PAMP9-20 and either 
9mM histamine, n= 3, or 3mM capsaicin, n=3, and between Anti-IgEand either histamine, n= 
4, or capsaicin, n=4. (E-G) Averaged Ca2+ imaging traces ±95% CI and heatmaps (Eʹ-Gʹ) of 
individual neurons activated by both PAMP9-20 and either CQ n= 42 (E-Eʹ), 5-HT, n= 42 (F-
Fʹ), or β-alanine, n = 38 (G-Gʹ). (H) Total number of neurons activated by indicated test 
compound in the presence of vehicle, cetirizine (H1R antagonist), or JNJ7777120 (H4R 
antagonist). For Anti-IgE: vehicle (veh) n= 4, cetirizine n=3, JNJ7777120 n= 3; for PAMP9-20: 
veh n=5, cetirizine n=3, JNJ7777120 n=3; for histamine (Hist): veh n=5, cetirizine n=3, 
JNJ7777120 n=3; and for 5-HT: veh n=3, cetirizine n=3, JNJ7777120 n=3. (C-I) Mean plus 
s.e.m. depicted. Open circles represent individual, imaged mouse DRGs. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; n.s. = not significant; two-tailed unpaired Student’s t-test. 
 
Given the role of Mrgprb2 in mediating non-histaminergic itch, we sought to 
investigate the relevance of Mrgprb2 in preclinical models of ACD, a chronic itch 
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disorder associated with mast cell involvement (Askenase et al., 1983; Dudeck et al., 
2011; Gimenez-Rivera et al., 2016; Grimbaldeston et al., 2007). ACD is a type IV 
hypersensitivity reaction that typically presents as an intensely pruritic, eczematous skin 
rash that is not amenable to antihistamine treatment (Kostner et al., 2017). In three 
separate models of ACD, squaric acetyl dibutyl acid (SADBE)- (Fu et al., 2014), 
oxazolone, and dinitrochlorobenzene (DNCB), treated mice exhibited significantly 
elevated itch compared to vehicle-treated controls. In all three models, Mrgprb2-/- 
animals scratched substantially less than WT mice (59% reduction in SADBE, 46% 
reduction in oxazolone, 44% reduction in DNCB) (Figure 29A-C). Compared to vehicle-
treated skin, DNCB-treatment resulted in an enrichment of immune cells as measured by 
CD45+ cell numbers; however, DNCB-treated Mrgprb2-/- skin had significantly lower 
CD45+ cell counts compared to WT skin (Figure 29D, G). Both WT and Mrgprb2-/- mice 
had similar ear skin thickness associated with ACD (Figure 30A). Further, Mrgprb2-/- 
mice were not protected from itch in the setting of either atopic dermatitis 
(MC903/calcipotriol) or dry skin (acetone:ether (1:1)-elicited), indicating that Mrgprb2 
preferentially regulated ACD-associated itch (Li et al., 2006; Miyamoto et al., 2002) 
(Figure 30B-C).  
 Mast cells modulate ACD-associated inflammation (Askenase et al., 1983; 
Dudeck et al., 2011; Gimenez-Rivera et al., 2016; Grimbaldeston et al., 2007). Indeed, 
compared to healthy control skin, lesional skin from ACD had increased numbers of mast 
cells as determined by avidin staining (Figure 29E-F). Multiple Mrgprb2/X2 agonists 
have been identified to be upregulated in ACD skin (El-Nour et al., 2006; Scholzen et al., 
2001). Here, we found that expression of PAMP1-20, an Mrgprb2/X2 agonist, was 
    
 









































Figure 29. Mast cell Mrgprs mediated a component of murine allergic contact dermatitis 
(ACD) itch, and PAMP1-20, an MRGPRX2 agonist, is upregulated in human ACD skin. 
(A-C) Scratching bouts in WT and Mrgprb2-/- animals with ACD. For all compounds, vehicle 
was acetone: olive oil (4:1 v/v). (A) ACD elicited by Squaric acid dibutyl ester (SADBE). Veh: 
WT n= 8, B2 -/- n= 6; SADBE: WT n=13, B2 -/- n=12. (B) 2-Phenyl-5-oxazolone (oxazolone). 
WT n= 11, B2 -/- n= 13. (C) 1-Chloro-2,4-dinitrobenzene (DNCB). WT n= 9, B2 -/- n= 8. (D) 
Representative flow cytometry plots of DNCB-treated ear skin and vehicle treated ear skin 
from WT and B2 -/- animals. Numbers indicate the percentage of cells within boxes. (E-Eʹ) 
Representative images of control (E) and ACD (Eʹ) human skin stained with avidin-FITC. White 
arrows indicate positive staining. Scale bar is 100 µM. (F) Number of avidin stained cells per 
square millimeter. Each circle represents a separate section. CTRL n= 5; Contact dermatitis 
n= 5. (G) Number of CD45+ leukocytes per biopsy from DNCB- and Vehicle-treated WT and 
B2 -/- mouse ear skin. Open circles represent independent samples from separate mice. For 
Veh: WT n=3, B2 -/- n=3. For DNCB: WT n=12, B2 -/- n=19. (H-Hʹ́ ) Representative images of 
control (H) and ACD human skin (Hʹ-Hʹ́ ) stained with either anti-PAMP (1-20) (human) 
antiserum (H-Hʹ) or antiserum preabsorbed with excess PAMP1-20 peptide (Hʹ́ ). Hʹ and Hʹ  ́
are from adjacent sections from the same patient. (I) Number of PAMP1-20 positive cells as a 
percentage of DAPI. Control = 0/1616; ACD = 1669/2071; ACD preabsorbed = 63/2097. ***, P 
< 0.001; by chi-square test. Samples from at least 5 different ACD patients were tested. (A-G) 
Mean plus s. e.m. depicted. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s. = not significant; two-
tailed unpaired Student’s t-test. 
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similarly upregulated in ACD patient skin while being undetectable in healthy control 
skin (Figure 29H-I). Adrenomedullin, the PAMP1-20 precursor, is produced by 
keratinocytes (Kapas et al., 2001). In support of this, we observed that anti-PAMP1-20 
staining was specific to epidermis (Figure 29H-I). A preabsorption control with PAMP1-
20 peptide inhibited staining, supporting the specificity of the anti-serum used (Figure 
29Hʹʹ). Collectively, these findings support the hypothesis that mast cell-expressed 
Mrgpr signaling plays a role in the pathogenesis of ACD-associated itch in both mice and 
humans.  
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4. Discussion 
In this thesis, I set out determine the role that Mrgprs, both sensory neuron- and 
mast cell-expressed, play in clinically relevant chronic itch conditions. Specifically, I 
examined the potential function of Mrgprs in mediating itch associated with two 
conditions: cholestatic pruritus and allergic contact dermatitis. Over the course of the 
thesis, I presented evidence that Mrgpra1/MRGPRX4 are receptors for bilirubin involved 
in cholestatic pruritus. I showed additional data that MRGPRX4 is not just a receptor for 
bilirubin but also activated by bile acids. Finally, I demonstrated that activation of mast 
cell-expressed Mrgprs resulted in nonhistaminergic itch and that Mrgprb2/ and 
MRGPRX2 are involved in allergic contact dermatitis itch.  
4.1 Mrgpra1/X4 in cholestatic pruritus 
Bilirubin has been widely studied as a neonatal neurotoxin and disease biomarker 
and not as a pruritogen. Our results revealed that bilirubin is a pruritogen that evokes itch 
by binding and activating MRGPRs on sensory neurons and may be an overlooked source 
of cholestatic patients’ itch. The KD of bilirubin for Mrgpra1 and MRGPRX4 suggests 
that bilirubin likely interacts and activates these receptors in individuals with markedly 
elevated bilirubin and not in healthy people. More narrowly in hepatobiliary diseases 
such as cholestasis, our data supports a model in which bilirubin is one of several 
pruritogens that contributes to itch. Genetic deletion of either MRPGRA1 (A1 KO) or 
bilirubin (BVR KO) strongly attenuates itch. However, mutant mice still exhibit greater 
itch compared to untreated mice. This suggests that additional pruritogens contribute to 
itch in hepatobiliary disease, a model which is consistent with the diverse and complex 
presentations of patients suffering from cholestatic pruritus. These other responsible 
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pruritogens could include bile acids, endogenous opioids, and LPA. While bilirubin-
altering therapies may be effective in reducing itch, not every patient who suffers from 
hepatobiliary pruritus is jaundiced. Accordingly, in these patients, disease-altering 
therapies targeting other pruritogens would be applicable.  
Although our findings demonstrate that bilirubin is pruritic, not every patient with 
jaundice experiences itch (the flip side of the previously referenced scenario). For 
example, patients with genetic hyperbilirubinemias such as Dubin-Johnson syndrome, a 
disorder involving mutations in the bilirubin transporter ABCC2, or Crigler-Najjar Type 
1, a disorder involving mutations in the bilirubin glucuronosyltransferase UGT1A1, 
rarely complain of pruritus (Levitt and Levitt, 2014; Van Der Veere et al., 1996). 
Moreover, neonates can have high levels of bilirubin in their skin but not itch. Bilirubin 
thus appears to exert selective pruritic activity in certain contexts, which we hypothesize 
may derive from its dynamic biophysical behavior and complex network of interactions. 
In isolated genetic hyperbilirubinemias, few – if any – other organic metabolites 
are elevated. In contrast, in cholestasis, numerous metabolites are elevated in addition to 
bilirubin (Alemi et al., 2013; Jacobsen and Broderson, 1983; Kalir et al., 1990; Kozaki et 
al., 1998). These metabolites would be expected to have large effects on bilirubin 
chemistry and biology. For example, in normal serum, even high levels of bilirubin are 
effectively buffered by albumin. In contrast, bilirubin’s affinity for albumin and other 
lipoproteins would be disrupted in cholestatic serum by numerous bile agents also 
upregulated (Ostrow and Celic, 1984; Rege et al., 1988). Accordingly, we hypothesize 
that bilirubin is more likely to be bound to albumin in isolated hyperbilirubinemias than 
in cholestasis. Thus, in isolated hyperbilirubinemia, despite elevated serum bilirubin 
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levels, bilirubin would be less likely to enter the skin where itch fibers and Mrg receptor 
reside. Notably, a metric with high positive predictive value for cholestatic pruritus is the 
Mayo risk score, an aggregate score that considers both serum bilirubin and albumin 
levels (Talwalkar et al., 2003). The Mayo risk score predicts that itch will increase with 
rising bilirubin and decreasing albumin levels. In this scenario, bilirubin would be less 
likely to be bound to albumin and thus free to diffuse into skin.  
In the specific case of Crigler-Najjar patients who have jaundice yet do not 
complain of itch, standard bilirubin-altering treatments like phenobarbital and light 
therapy may be effectively masking underlying pruritic activity. Light therapy induces 
photoisomerization and/or photolysis of bilirubin, altering its structure and activity, and 
phenobarbital decreases global neuronal excitability.  
In addition to bilirubin, I demonstrated that MRGPRX4, but not Mrgpra1, is also 
activated by numerous unconjugated and conjugated bile acids. Bile acids activated 
humanized (+X4) mouse sensory neurons at higher percentages, indicating that these 
compounds are capable of interacting with neuronally expressed receptor. Humanized 
mice scratched more in response to both acute injection of bile acids and a chronic model 
of cholestatic itch. Cholestatic itch in humanized mice rose in conjunction with plasma 
bile acid concentration. Our results strongly support that MRGPRX4 is a receptor for bile 
acids. Given the receptor’s expression pattern in humans, it is possible that MRGPRX4 
mediates a bile acid-component of cholestatic itch. 
Despite being structurally similar, bile acids displayed a wide range of affinity for 
MRGPRX4. Cholic acid, the least potent bile acid, has 3, 7, and 12 hydroxyl groups. 
In contrast, the higher potency bile acids, DCA and UDCA, have only a 3 hydroxyl and 
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a 12 or 7β hydroxyl group, respectively. Based on this, we hypothesize that bile acid 
potency for MRGPRX4 is structurally determined by hydroxyl groups at the 7 and 12 
position carbons, and their effects on hydrogen bonding, sterics, and water solubility. 
Cholesterol has no detectable activity towards MRGPRX4 and is most clearly structurally 
different from bile acids in that cholesterol exhibits more planarity among its four rings 
due to a double bond between carbons 5 and 6. 
UDCA, one of the more potent determined agonists of MRGPRX4, has been 
shown to reduce itch in a significant number of patients suffering from pruritus 
associated with intrahepatic cholestasis of pregnancy and primary biliary cholangitis (de 
Caestecker et al., 1991; Glantz et al., 2008; Matsuzaki et al., 1990). Our data suggests 
that, UDCA could promote itch via MRGPRX4. There are many possible explanations 
for this apparent discrepancy. Notably, UDCA may act as an anti-pruritic agent by 
decreasing hepatocellular injury, inflammation, and fibrosis (de Caestecker et al., 1991; 
Glantz et al., 2008; Matsuzaki et al., 1990). UDCA treatment also does not appear to 
increase total serum bile acid levels despite being a bile acid. Rather, while serum UDCA 
levels increase, UDCA either decreases or leaves total serum bile acids unchanged. The 
molecular mechanisms by which UDCA improves cholestatic injury could result from a 
combination of effects, such as improving hepatocellular function, immunosuppressive 
effects through unknown mechanisms, and improvements in bile acid flow through the 
digestive system. Improvement of cholestasis in the absence of total bile acid serum level 
elevation would be expected to improve pruritus and is consistent with our data.  
 The role of bile acids in eliciting cholestatic itch in patients is complex. 
Cholestyramine, a bile-acid chelating resin, aids in secretion and is front-line therapy for 
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cholestatic pruritus. In a double-blind trial, cholestyramine was shown to be effective for 
treating itch. However, more recently, colesevalam, a bile-acid binding resin many times 
more effective than cholestyramine, displayed contradictory trial results (Kuiper et al., 
2010). This discrepancy in the effectiveness of serum bile acid modulating therapy is 
buttressed by clinical observations that serum bile acid levels do not correlate with 
pruritus. Not all patients with pruritus have elevated serum bile acids, and not all patients 
with elevated serum bile acids exhibit itch. For example, serum bile acid levels are 
maximally elevated during liver failure, but these patients often report little to no itch.  
These data reaffirm our hypothesis that cholestatic itch is multifactorial, with 
numerous pruritogens present in bile that activate a variety of neuronal receptors. 
MRGPRX4 is activated by both bilirubin and bile acids, supporting a model whereby 
both bile acids and bilirubin contribute to cholestatic itch via agonism at the same 
receptor, MRGPRX4. Even without taking additional pruritogen-receptor interactions 
into account, serum levels of a single marker would not be expected to perfectly correlate 
with itch. Therefore, to properly interpret correlations relying on serum metabolite values, 
multiple components would likely need to be considered in relation to itch. Additional 
hypotheses for this lack of correlation include possible desensitization and internalization 
of MRGPRX4 during late-stage liver failure and/or populational polymorphisms in 
MRGPRX4 sequence that alter receptor affinity. Further research is required to address 
these possibilities. However, despite these open questions, our data suggests that 
MRGPRX4 may be a potential therapeutic target for cholestatic itch. 
4.2 Mrgprb2/X2 in allergic contact dermatitis and mast cell itch. 
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It is widely believed that mast cells, via the IgE/FcεRI-histamine axis, contribute 
to itch in a number of inflammatory skin disorders. However, histamine antagonists have 
been ineffective in treating many forms of allergic itch, suggesting that alternative 
mechanisms exist (Kamo et al., 2014; Liu et al., 2016; Usatine and Riojas, 2010). Here, 
we demonstrated that Mrgprb2 activation of mast cells, compared to classical IgE-
mediated activation, promoted the differential release of pruritogens like tryptase beta 2 
and evoked non-histaminergic itch. However, due to the complex composition of mast 
cell granules, Mrgprb2-associated non-histaminergic itch is likely provoked by a number 
of pruritogens in addition to tryptase. Although largely histamine independent, a minor 
component of Mrgprb2-associated itch may be histaminergic as antihistamines slightly 
reduced the number of sensory neurons activated by PAMP9-20. Conversely, IgE-FcεRI 
associated itch displayed a non-histaminergic component that was resistant to histamine 
receptor antagonism. These findings suggest that, despite clear divergence, some overlap 
exists between Mrgprb2- and FcεRI-mediated mast cell itch.  
PAMP9-20-excited neurons associated best with Mrgprd+ itch neurons while anti-
IgE-associated neurons consistently overlapped with histamine-sensitive neurons. In 
sensory neurons, H1R expression overlaps more with 5ht1f and Mrgpra3 expression and 
less with Mrgprd (Usoskin et al., 2015). Thus, the difference in sensory neuron activation 
between PAMP9-20 and anti-IgE could be explained by differential mast cell 
degranulation and release of compounds like tryptase beta 2. Tryptases cleave proteinase-
activated receptors (PARs) present on itch-sensory neurons (Fu et al., 2014; Liu et al., 
2011; Shimada et al., 2006). Further, different forms of PARs like PAR4 and PAR2 are 
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preferentially expressed on Mrgprd+ and 5ht1f+ neurons, respectively (Usoskin et al., 
2015).  
Many chronic allergic itch conditions with mast cell involvement are refractory to 
histamine antagonists, indicating that alternative itch mechanisms exist (Kamo et al., 
2014; Liu et al., 2016; Usatine and Riojas, 2010). ACD is one such condition with an 
enormous occupational health burden (Peiser et al., 2012). In ACD skin, multiple 
potential Mrgprb2 and MRGPRX2 agonists are upregulated. Indeed, we show that 
Mrgprb2-/- mice were protected from ACD- associated itch and that PAMP1-20 was 
enriched in lesional ACD patient skin. Despite a significant reduction in pruritus, 
Mrgprb2-/- animals had residual ACD itch which could result from alternative 
mechanisms like IL-33 activation of neuronal ST2 and T-cell release of IL-31 (Liu et al., 
2016; Takamori et al., 2018). Both mast cells and MRGPRX2 agonists are upregulated in 
atopic dermatitis and psoriasis (Nattkemper et al., 2018). However, Mrgprb2-/- animals 
did not exhibit reduced itch after topical MC903 treatment, a model of atopic dermatitis. 
However, whether MRGPRX2 is an alternative mast cell-associated target in pruritus of 
atopic dermatitis in humans remains to be defined. Notwithstanding this, our murine 
studies suggest that Mrgprb2 played a preferential role in ACD compared to atopic 
dermatitis or dry skin.   
4.3 Future directions  
 
Mrgprs, as receptors for non-histaminergic pruritogens, could play a role in other 
chronic itch conditions. One prevalent condition in which Mrgpr involvement remains to 
be tested is uremic itch, itch occurring in the context of renal failure. In uremia, numerous 
potential Mrgpr agonists are upregulated including adenine and bilirubin byproducts like 
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urobilinogen. Intriguingly, adenine has been shown to be agonist of Mrgpra9/a11, murine 
Mrgprs, potentially linking Mrgpr signaling to uremic itch. A key experiment to be 
performed would be to perform a model of uremic pruritus, such as 5/6 nephrectomy, in 
WT and Cluster KO littermates and assess for differences in itch. 
Thr vast majority of Mrgpr agonists are low potency, micromolar agonists, 
including those mentioned in this thesis. Thus, a true physiological ligand with 
nanomolar affinity for most Mrgprs, mouse and human, has yet to be identified. The 
major exception may be BAM8-22 activation of Mrgprc11/X1 which fits several criteria. 
One, it is an endogenously produced peptide. Two, it has low nanomolar affinity for 
receptor. Three, it has in vivo effects dependent on receptor activity. However, outside of 
this interaction, there are no examples of ligand-receptor pairings that fit these criteria. 
Small-molecule screens for agonist activity against a variety of Mrgprs would be useful 
in potentially identifying high-affinity interactions as relevant molecular backbones are 
detected, which could be used to model additional ligands. 
Mrgprs, as GPCRs with specific expression, make for attractive drug targets. 
Assessing whether they could play a role in human pathophysiology would likely be of 
substantial clinical benefit. This work was performed using mice as models of disease 
behavior. There are many outstanding questions to address in order to translate these 
findings to the clinic.  
While mice scratch to bilirubin and bile acids, the picture is more complicated in 
humans. Only one molecule, autotaxin, has ever been demonstrated to correlate with 
cholestatic itch in humans, and serum levels of bilirubin and bile acids do not correlate 
with itch. Additionally, there exists numerous clinical examples of non-pruritic jaundice 
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ranging from acquired diseases like hemolytic anemia to genetic deficiencies in bilirubin 
processing enzymes like Dubin-Johnson and Crigler-Najjar. Additionally, the itch 
literature is replete with substances which elicit robust, reproducible itch in mice and very 
little, if any, in humans such as LTB4. Of note, even the canonical Mrgpr pruritogen, 
chloroquine, elicits severe itch in mice and none in humans (Data shared from Robert 
LaMotte’s lab at Yale). An important translation of our study’s findings, in regards to 
bilirubin, would be whether injection of bilirubin into humans elicits itch. We are actively 
trying to address this question in a collaboration with the LaMotte lab which has IRB-
approval to do this study. In July 2018, I volunteered in the study and reported robust itch 
lasting approximately 30 min. upon injection of both unconjugated (10L of 2mM) and 
conjugated bilirubin (10L of 2mM). Bilirubin elicited itch without pricking, tingling, or 
stinging sensations. Distinct from pathophysiological, jaundiced itch, the molecule 
elicited wheal and flare indicating some mast cell involvement. Jaundiced patients do not 
display wheal and flare, indicating that acute injection of high dose bilirubin can 
artificially activate mast cells. However, the itch sensation is not believed to be entirely 
due to this confounding mast cell involvement as psychophysical studies of mast cell 
activation almost never results in isolated itch, but rather, presents as mixed itch and pain 
in the form of pricking and stinging. This study is still ongoing as more volunteers are 
needed to have confidence in the data. 
Another important future direction is to understand how MRGPRX4 
polymorphisms may affect receptor function. Based on publicly available populational 
sequencing data, MRGPRX4 is an extremely polymorphic gene with many identified 
SNPs causing missense mutations. A few of these mutations appearing at high frequency 
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are associated with drastic changes in receptor response to agonists (Kozlitina et al., 
2019). High-frequency appearing polymorphisms of MRGPRX4 should be tested for 
response to bilirubin, bile acids, and other published agonists like nateglinide in order to 
more fully understand how these polymorphisms might impact function. Cholestatic 
patients, with itch and without itch, should be assessed for possible polymorphic 
differences in MRGPRX4. We showed the skin bilirubin levels correlate with itch in 
mice. This data should be repeated with human skin samples from cholestatic patients 
with corresponding psychophysical itch scores. In parallel, small-molecule screens for 
antagonists and inverse agonists of MRGPRX4 should be conducted in order to identify 
lead compounds for treating cholestatic itch. Similarly, small-molecule screens for 
antagonists and inverse agonists of MRGPRX2 should be conducted in order to identify 
lead compounds for treating allergic contact dermatitis and other mast cell-associated itch 
conditions. 
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